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Evolution of breast cancer treatment
Breast cancer is the most common female cancer, the second most common cause of
cancer death in women (after lung cancer), and the main cause of death in women
aged 45 to 55 years. In the Netherlands, the lifetime risk of developing breast cancer
is 11% amongst women [1]. In the United States similar rates are reported. This
translates into 11.500 new cases of breast cancer in the Netherlands and 211.240 new
cases of breast cancer in the United States each year. In addition, 1 out of 20 to 25
women will die because of breast cancer [2].
Currently, overall survival rates for breast cancer are 80% after 5 years and 69% after
10 years of follow-up respectively [3].
Although mortality trends have been declining since 1992, the incidence of breast
cancer in the Western World has risen since then, possibly due to the introduction of
breast cancer screening programs. This means that although breast cancer treatment
has improved over the past three decades, breast cancer still is a major subject of
concern in terms of healthcare in our society [4].
Originally, treatment of breast cancer consisted of surgery alone and was aimed at
aggressive locoregional eradication of tumor cells. In 1894 Halsted introduced the
radical mastectomy in an era where breast cancer was normally treated by wide local
excision alone which was associated with a high rate of locoregional recurrences [5].
The rationale of more aggressive locoregional therapy was based upon the hypothesis
that more extensive resection would provide a better chance of disease control. The
radical mastectomy implied “en bloc” removal of the breast, the overlying skin, both
the pectoralis major and minor muscles, and the entire axillary contents (level I, II,
and III nodes). The radical mastectomy resulted in a significant drop in local
recurrence rates, and it became the standard of care for the treatment of breast
cancer. However, despite the improvement in local control, the curative potential of
this operation remained limited. In one series that followed 1438 women who had
undergone radical mastectomy for 30 years, only 13 percent were free of disease,
while 57 percent had died of breast cancer [6]. Therefore, in the 1970-ies, it was
hypothesized that a less extensive operation, the modified radical mastectomy
(MRM), could be performed without compromising survival. The term MRM implied
complete removal of the breast tissue and the underlying fascia of the pectoralis
major muscle, and removal of some but not all of the axillary nodes (levels I and II).
Several prospective randomized trials documented equivalent survival rates with
MRM as compared to radical mastectomy, with less morbidity [7-10]. These findings
significantly changed the surgical approach to invasive breast cancer. More
importantly, however, it supported the concept that breast cancer was not a local
disease that spread contiguously, as Halsted proposed, but rather that systemic
disease was ultimately the main determinant of survival. Variations in the treatment
of local or regional disease were unlikely to affect survival.
While MRM was a less morbid procedure than radical mastectomy, it still required the
loss of the breast. The question arose as to whether the breast could be preserved
without compromising survival. Therefore breast-conserving therapy was introduced
in the seventh and eighth decade of the twentieth century. Breast conserving therapy
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refers to surgical removal of the tumor (with negative surgical margins) followed by
radiotherapy to eradicate any residual disease. Six randomized clinical trials directly
comparing breast conserving therapy with mastectomy and an overview of all
completed trials have shown equivalent survival between the two treatment
approaches although locoregional control rates after breast conserving therapy were
significantly lower than after modified radical mastectomy [11-20].
In addition to changes in locoregional strategy of breast cancer treatment, the
introduction of adjuvant polychemotherapy changed the concept of breast cancer
treatment dramatically.
Over the past few decades, many randomized trials have been undertaken of various
chemotherapy regiments for early breast cancer, and the data of these trials were
included in quinquennial meta-analyses published by the Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG).
This meta-analysis summarized results of every randomized trial that began before
1990 and involved treatment groups that differed only with respect to the chemo-
therapy regimens that were being compared. In 47 trials comparing combination
chemotherapy with no chemotherapy, a significant reduction in mortality occurred in
patients receiving chemotherapy irrespective of nodal status (negative vs. positive),
estrogen receptor (ER) status (ER-rich vs. ER-unknown, or ER-poor), and whether or
not hormonal therapy was administered. The benefit of chemotherapy, however, did
vary substantially according to patient age and menopausal status. For all women
younger than 50 years at randomization, combination chemotherapy improved 10-
year survival from 71% to 78% for those with node-negative disease (an absolute
benefit of 7%), and from 42% to 53% for those with node-positive disease (an absolute
benefit of 11%). For women between 50 and 69 years at randomization, combination
chemotherapy improved 10-year survival from 67% to 69% for those with node-
negative disease (an absolute gain of 2%), and from 46% to 49% for those with node-
positive disease (an absolute gain of 3%) [21, 22].
European Organization for Research and Treatment of Cancer
All studies presented in this thesis are derived from trials originated and conducted
by the EORTC Breast Cancer Group. The work of this thesis has to a significant extent
been performed during a fellowship at the Data Center of the European Organization
for Research and Treatment of Cancer (EORTC) in Brussels, Belgium.
This organization was founded in 1962 by oncologists working in the main cancer
research institutes of the EU countries and Switzerland. It was named Groupe
Europe´en de Chimiothe´rapie Anticance´reuse (GECA), and became the European
Organization for Research and Treatment of Cancer (EORTC) in 1968.
In 2004, group members entered a total of 4508 new patients in EORTC trials. An
additional 971 patients from other research groups were treated as part of the
intergroup study scheme managed by the EORTC Data Center, and in 2005 no less than
85 studies are open for entry and are being conducted by the EORTC Data Center.
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The EORTC Breast Cancer Group is a multidisciplinary group involving surgeons,
radiation oncologists and medical oncologists, pathologists, radiologists, biologists,
psychologists and research fellows. Currently, the Group includes 17 institutions with
the status of active member and 75 institutions with the status of probationary
member. The main activity of the Group has been to carry out large clinical studies
covering a wide spectrum of breast cancer patients. Translational research evaluating
correlations between clinical outcomes and biologic tumor characteristics has
become a high priority as well.
Examples of such investigations include studies presented in this thesis. Current
activities include the potential predictive value of P53 gene mutation in primary
chemotherapy of locally advanced breast cancer (EORTC 10994) and detection of
micrometastasis in sentinel lymph nodes by PCR (EORTC 10981) and the role of
radiotherapy after sentinel node biopsy in axillary node positive patients (AMAROS).
Recently a hereditary task force addressing several aspects of hereditary breast
cancer has been installed. This group is performing a large retrospective study on
archival tumor in paraffin selected from 8000 patients previously treated in
randomized EORTC trials, comparing treatment outcomes from patients carrying a
proven BRCA 1 or 2 mutation or non-carriers.
The Group has prepared and is continuously updating the Manual for Clinical
Research in Breast Cancer, used as a reference for protocol elaboration, data collection
and reporting of results (recently also online: www.bco.org breast cancer online). This
manual summarizes the major points in assessment, staging, treatment and follow-
up of breast cancer patients. It enhances the uniformity of definitions and procedures
in the various breast cancer protocols.
Within the last three years the number of patients included in clinical studies is
stable: 1008 in 2002, 1020 in 2003 and in 2004 it was 856. A total of 9 clinical trials
were open for the accrual in 2004.
Additionally, thousands of patients included in previous studies have been under
continuous follow up in order to obtain long term results.
Rationale and aims of this thesis
In this thesis, several questions regarding specific issues both in locoregional
treatment and in systemic treatment are evaluated. Therefore, the thesis is divided
into three parts. Part I addresses questions concerning systemic treatment. Part II
studies several aspects of locoregional treatment and outcome, and finally part III
discusses the question whether specific tumor characteristics can discriminate very
young patients with early stage breast cancer with a good outcome in terms of
survival from similar patients who have a poor outcome.
Part I 
Concerning adjuvant systemic polychemotherapy, the aspect of timing of
administration of chemotherapy is studied. Experimental studies using murine
models in the seventies and the eighties suggested that the administration of
chemotherapy before or immediately after removal of the primary breast tumor
resulted in a significant decrease in tumor cell proliferation in metastases and a
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decrease in the upregulation of growth factors due to surgery [23-27].
Therefore, we tested the hypothesis that adjuvant chemotherapy given before or
immediately after surgery improves disease outcome in terms of survival and
locoregional control. In this thesis, two prospective studies conducted by the EORTC
Breast Cancer Group are presented in which neoadjuvant and perioperative
chemotherapy are evaluated.
EORTC trial 10854 studied the question whether or not chemotherapy given directly
after surgery would yield better results in terms of locoregional control, disease-free
survival and overall survival. Perioperative chemotherapy consisted of one short inten-
sive course of fluorouracil, doxorubixin, and cyclophosphamide, administered within
36 hours after surgery. The eleven-year follow up results are presented in this thesis.
EORTC trial 10902 was conducted to study whether or not the administration of
neoadjuvant chemotherapy in early breast cancer patients would lead to improved
treatment outcome as well. This thesis reports the 5-year follow up results of EORTC
trial 10902. The study group received 4 courses of fluorouracil, epirubicin, and
cylclophosphamide, administrated before surgery. The control group received the
same chemotherapeutic regimen given postoperatively.
Part II
As described above, breast-conserving surgery is similar effective in terms of long
term outcome as compared to modified radical mastectomy but is associated with a
higher locoregional recurrence rate [28]. The rationale for this finding can be
explained by the fact that breast cancer is a systemic disease rather than a loco-
regional disease. On the other hand, women who experience a locoregional
recurrence have unfavorable prognosis and not surprisingly, a locoregional recurrence
is a strong independent prognostic factor associated with unfavorable survival rates.
Nevertheless, the general assumption is therefore that more aggressive surgery does
not lead to better survival.
In relative contradiction with these findings are better survival rates described with
subsequent adjuvant radiotherapy after modified radical mastectomy compared to
modified radical mastectomy alone [29-32].
Therefore, we hypothesized that any improvement in long term outcome due to more
aggressive locoregional treatment should be accompanied by an improvement in
locoregional control.
Next, we hypothesized that a subset of patients can be identified that might benefit
from more aggressive locoregional therapy at time of diagnosis to prevent an isolated
locoregional recurrence. This subset consists of patients that developed a locoregional
recurrence after primary treatment, received therapy and eventually developed
systemic disease, but only after being disease-free for a long follow-up period. These
are patients in which locoregional recurrence is an instigator rather than an
associative factor for subsequent metastatic disease.
Therefore, we studied the question whether it is possible to identify patients in which
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the prevention or successful treatment of locoregional recurrences could lead to
better disease outcome. In addition, we studied the association between tumor
characteristics and locoregional recurrence.
Part III
In the last part of this thesis, tumor characteristics of breast cancer in the very young
breast cancer patient are studied. The prognostic impact of young age at onset is well
known. However, the underlying pathophysiological mechanisms remain uncertain.
Since patient age is a well-established risk factor associated with poor local control as
well as unfavorable outcome in terms of survival [33-38], we studied the possibility to
divide the very young patient group into a good- and a bad prognosis cohort. Next, we
tried to gain further insight in chemotherapy responsiveness in hormone receptor
positive- and hormone receptor negative young breast cancer patients groups since
the effect of adjuvant systemic chemotherapy in the former group has been subject of
discussion due to alternative treatment strategies and impaired chemosensitivity in
this patient group [39-43].
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CHAPTER 2
Improved survival after one course of
perioperative chemotherapy in early breast
cancer patients: long-term results from the
European Organization for Research and
Treatment of Cancer (EORTC) Trial 10854
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Abstract
The aim of this study was to examine whether one course of perioperative polychemotherapy
yields better results in terms of survival, progression-free survival (PFS) and locoregional control
than surgery alone in early stage breast cancer. From 1986 to 1991, 2795 patients with stage I/II
breast cancer were randomised to receive either one perioperative course of an anthracycline
containing chemotherapeutic regimen within 36 hrs after surgery or surgery alone. Patients were
followed-up for overall survival, PFS and locoregional recurrence. The median follow-up period at
time of the analysis was 11 years. PFS and locoregional control were significantly better (P=0.025
and P=0.004, respectively) in the perioperative chemotherapy arm. Node-negative patients seemed
to benefit most from the perioperative FAC. Patients who received perioperative chemotherapy
and locoregional therapy alone had significantly better overall survival rates than patients who
received locoregional therapy alone (P=0.004). Patients who received additional systemic therapy
did not seem to benefit from one course of perioperative chemotherapy (P=0.65). One course of
perioperative polychemotherapy does improve PFS and locoregional control in early stage breast
cancers. This effect is still present after 11 years of follow-up.
Introduction
Systemic adjuvant therapy has been shown to improve both disease-free survival and
overall survival in breast cancer patients [1]. Over the past three decades, many
investigators have studied the benefits of adjuvant chemotherapy in breast cancer.
However, the significance of the timing of administration of chemotherapy in relation
to locoregional treatment is still a matter of debate. Experimental studies, as well as
mathematical hypotheses [2–6], have demonstrated that early timing of
chemotherapy may be more effective than standard postoperative administration of
chemotherapy.
Several randomised trials studying the effect of the administration of one dose of
chemotherapy immediately after surgery with or without subsequent prolonged
chemotherapy  demonstrated better disease-free or relapse-free survival rates using
this therapeutic regimen [7–9].
In the European Organization for Research and Treatment of Cancer (EORTC) trial
10854, of which preliminary results have been published previously, a similar effect
was observed at a median follow-up time of 41months [10]. In this report, we will
focus on the effect of perioperative chemotherapy after long-term follow-up.
Patients and methods
Patient characteristics
Eligibility requirements, randomisation procedures, surgical and radiation techniques
used, characteristics of patients and tumours, and the distribution of patients among
the treatment groups have been published previously [10]. In brief, eligible patients
had primary operable breast cancer, T1-3, N0-2, M0, and had to be younger than 70
years of age at the time of randomisation.
Improved survival after one course of perioperative chemotherapy in early breast cancer patients
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Exclusion criteria were bilateral breast
cancer, previous treatment for breast
cancer and previous systemic treatment
for other cancers, distant metastases, and
a poor World Health Organization (WHO)
performance (>2). Patients were
randomised to either receive one course
of perioperative chemotherapy within 36
hrs after surgery or surgery alone. Patient
characteristics are shown in Table 1.
Patients who were younger than or equal
to 50 years of age at the time of diagnosis
were classified as premenopausal.
Patients older than 50 years were
considered postmenopausal. Tumour
oestrogen receptor status (ER) was
measured using a biochemical assay
according to the best method locally
available at every institution. A value of
510 fmol ER per mg protein was
considered positive and a value of 
0–9 fmol ER per mg protein was
considered negative [11]. No information
on the progesterone receptor status was
collected. In the subgroup of node-
negative premenopausal patients, ER status was also measured by immunohisto-
chemistry in a central pathology review.
Treatment
Patients were treated with either (modified) radical mastectomy or breast-conserving
surgery. Perioperative chemotherapy consisted of one single course of 50 mg/m2
doxorubicin, 600 mg/m2 5-fluorouracil, and 600 mg/m2 cyclophosphamide (FAC),
administered intravenously (i.v.) within 36 h after surgery. Axillary lymph node-
positive premenopausal patients in the perioperative chemotherapy group were
recommended to receive an extra five cycles of cyclophosphamide, methotrexate and
5-fluorouracil (CMF). Node-positive patients, younger than 50 years, who did not
receive perioperative chemotherapy, were advised to have one conventional course of
FAC followed by five cycles of CMF after surgery. Adjuvant hormonal therapy at the
time was not routinely given in the management of breast cancer and the decision to
give tamoxifen was therefore left to the discretion of the respective investigators.
Radiotherapy was given in both arms. Postoperative radiation had to be started 6
weeks after surgery and was given in all cases in which surgery was considered not to
be radical. A detailed description concerning the administration of radiotherapy was
given previously [10].
Statistical considerations
The primary endpoint of the EORTC 10854 trial is overall survival. Secondary
Improved survival after one course of perioperative chemotherapy in early breast cancer patients
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endpoints are progression-free survival
(PFS) and locoregional recurrence as the
first event. PFS was defined as the time
between the date of randomisation and
the date of relapse (including secondary
primary tumours and contralateral breast
cancers) or death, whichever came first. A
locoregional recurrence was defined as
any recurrence in the breast or axilla.
Only recurrences which occurred before
the diagnosis of a distant metastasis
and/or a new primary tumour were
regarded as a locoregional recurrence as
the first event and added to the analysis.
Statistical calculations were performed
using the ‘intent-to-treat principle’. This
means that all data are used in the
statistical calculations, regardless of the
fact whether a patient was eligible or not.
PFS and overall survival curves, as well as
locoregional recurrence rates, were
estimated using the Kaplan–Meier
method [12] and log-rank tests for the
comparison of treatment effects were
also used [13]. Cox proportional-hazard
regression models [14] were used to
estimate hazard ratios (HR) with their




From May 1986 to March 1991, 2795
patients were enrolled from 16
institutions from nine different countries
onto this trial (Appendix). 41patien ts
were ineligible. 2793 patients were
included in the analysis. 2 patients, of
whom information concerning
randomisation was missing, were
excluded from the analysis. After a
median follow-up of 11 years, overall
survival (71% versus 74%) was not
significantly different between the two
treatment groups (HR=0.9; 95% CI:
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Figure 1. Overall survival
Figure 2. Progression-free survival
Figure 3. Locoregional recurrence as first event
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0.78–1.37; P = 0.14) (Fig. 1). However, PFS rates (53% versus 59%) are significantly
different in favour of the perioperative chemotherapy group (HR=0.88; 95% CI:
0.78–0.98; P = 0.025) (Fig. 2). In line with the PFS results, locoregional control (86%
versus 91%) was significantly different also in favour of the study-arm; (HR=0.69; 95%
CI: 0.54–0.89; P = 0.004) (Fig. 3).
Subgroup analyses
To study the effect of perioperative chemotherapy in the specified groups of patients,
subgroup analyses were carried out. However, one must interpret the outcome of
these analyses with caution, as these were not preplanned analyses and are therefore
only to be regarded as exploratory analyses.
Node-negative patients
1467 patients without axillary lymph node metastases were included in the trial.
Node-negative patients in the study-arm did not have a significant better overall
survival (HR=0.89; 95% CI: 0.70–1.13; P = 0.33) after perioperative FAC. However, a
significant effect of perioperative FAC was observed on the PFS rate (HR=0.83; 95% CI:
0.70–0.99; P = 0.035). In addition, perioperative chemotherapy did have a profound
effect on locoregional control in this subgroup, resulting in a significant difference in
the locoregional control rates (HR=0.67; 95% CI: 0.48–0.93; P = 0.018) in favour of the
study-arm.
Patients with T1 tumours 
Patients with small tumours who received perioperative FAC did not benefit
significantly in terms of overall survival (HR=0.86; 95% CI: 0.62–1.18; P = 0.34) and PFS
(HR=0.92; 95% CI: 0.73–1.17; P = 0.50). However, perioperative chemotherapy had a
marginally favourable effect on locoregional control (HR=0.64; 95% CI: 0.42–0.99; 
P = 0.047).
Premenopausal patients
Premenopausal patients have been established as the patients that benefit the most
from adjuvant chemotherapy for breast cancer. Patients younger than or equal to 50
years of age at the time of diagnosis were deemed to be premenopausal patients in
this study. Perioperative chemotherapy did not yield better overall survival rates
(HR=0.91; 95% CI: 0.72–1.15; P = 0.43) or PFS rates (HR=0.87; 95% CI: 0.73–1.05; P = 0.15)
in this subgroup. Moreover, the administration of one course of perioperative FAC did
not result in better locoregional control rates (HR=0.75; 95% CI: 0.53–1.05; P = 0.096).
Timing of administration
We presumed that if timing influences treatment efficiency, this effect could only be
demonstrated in patients who received extra adjuvant systemic therapy. To study the
‘timing-effect’ of one course of perioperative FAC, we therefore selected all patients
who received prolonged adjuvant systemic treatment. In total, 1198 patients were
included in the ‘timing’ analysis, but no effect of timing was found on overall survival
(HR=0.65; 95% CI: 0.78–1.17; P = 0.65) or PFS (HR=0.94; 95% CI: 0.80–1.12; P = 0.50),
respectively. In addition, no effect of timing was found on locoregional control
(HR=0.88; 95% CI: 0.59–1.31; P = 0.52).
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Perioperative FAC as the sole systemic
therapy
To test the absolute effect of one
perioperative course of FAC, we compared
the data of the patients in the control
group who did not receive adjuvant
systemic treatment with the patients
who received perioperative chemotherapy
alone in the study-arm. Patient
characteristics are listed in Table 2. In this
subset, which consisted of 1532 patients,
a significant difference in favour of the
perioperative chemotherapy group was
shown in terms of overall survival
(HR=0.80; 95% CI: 0.64–0.98; P = 0.035) and
PFS (HR=0.79; 95% CI: 0.67–0.93; P = 0.004)
(Figs. 4 and 5). Locoregional control was
also significantly better in the study-arm
(HR=0.60; 95% CI: 0.43–0.83; P = 0.0023)
(Fig. 6).
Type of surgery
Perioperative chemotherapy did not have
a significant effect on overall survival
when patients were compared according
to type of surgery (data not shown).
Interestingly, perioperative chemotherapy
has a significant impact on PFS (HR=0.84;
95% CI: 0.72–0.98; P = 0.031) and
locoregional control (HR=0.71; 95% CI:
0.52–0.97; P = 0.029) in patients who
underwent breast-conserving surgery, but
not in patients who underwent
mastectomy (HR=0.92; 95% CI: 0.78–1.08; 
P = 0.30 and HR=0.67; 95% CI: 0.43–1.04; 
P = 0.074, respectively).
ER-status
ER-status was known in 89% of the
patients. 65% was ER-positive, 24% were
ER-negative. In the ER-positive
population, patients who received perioperative chemotherapy had a marginally
significant better locoregional control rates (HR=0.71; 95% CI: 0.52–0.98; P = 0.04).
Perioperative chemotherapy did not have a significant effect on overall survival and
PFS in ER-positive patients. In ER-negative patients, locoregional control as well as
PFS or overall survival rates were not significantly altered by perioperative
chemotherapy.
Improved survival after one course of perioperative chemotherapy in early breast cancer patients
Figure 4. Overall survival in patients with 1
course of peri-operative FAC and no further
systemic therapie versus patients treated with
locoregional therapie alone.
Figure 5. Progression-free survival in patients
with 1 course of peri-operative FAC and no
further systemic therapie versus patients
treated with locoregional therapie alone.
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Discussion
This trial was set up primarily to study
whether one course of chemotherapy
given directly after surgery would yield
better results in terms of prognosis than
surgery alone in early stage breast cancer
patients. As demonstrated in the main
analyses, our results firmly demonstrate
that perioperative chemotherapy after
surgery leads to better locoregional
control than surgery alone. We also
showed that one course of perioperative
FAC significantly improves progression-
free survival rates.
Moreover, in a subset of patients who
received locoregional treatment alone,
one course perioperative FAC resulted in
significant higher survival rates for those
given perioperative chemotherapy. However, when patients who also received
prolonged courses of chemotherapy or patients who received hormonal therapy were
studied, no significant effect of perioperative administration of FAC could be shown.
Ever since chemotherapy became part
of the therapeutic strategy against
breast cancer, timing has been a
matter of discussion. Several trials
have studied early administration of
(poly) chemotherapy after surgery
[7–9,15–17]. These trials and their
overall results are listed in Table 3. To
date, however, no evidence of a
significant effect of early timing of
chemotherapy after primary tumour
removal on treatment outcome has
been demonstrated.
Since EORTC trial 10854 was initiated
in 1986, the indication guidelines of
adjuvant chemotherapy have shifted
substantially. In the 1980s,
chemotherapy was given on the basis
of nodal- and menopausal status. At
present, the decision to administrate
chemotherapy is based on a combined
evaluation of tumour stage, tumour
grade and menopausal status in order
to pursue a 10% disease-free survival
gain after 10 years [19]. This shift has
Improved survival after one course of perioperative chemotherapy in early breast cancer patients
Table 2. Patient characteristics; patients treated
with 1 course of peri-operative FAC and no further
systemic therapy versus patients treated with
locoregional therapy alone
Figure 6. Locoregional recurrence in patients
with 1 course of peri-operative FAC and no
further systemic therapie versus patients
treated with locoregional therapie alone
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led to a higher fraction of early stage breast cancer patients receiving chemotherapy
nowadays compared with two decades ago. If this trial was to be executed now, the
subgroup of patients who would not receive additional systemic therapy would be
much smaller. The question therefore is whether patients in which additional
systemic therapy is not indicated nowadays (i.e. node-negative patients with small
tumours and favourable histological parameters) would benefit from one course of
chemotherapy.
Based upon our results, this question is difficult to answer. However, the presented
results can be of use in designing future clinical trials.
However, the outcome that one course of chemotherapy as a sole systemic therapy is
able to induce a modest, but significant increase in overall survival and better
locoregional control rates in a subset of low-risk breast cancer patients regardless of
the tumour stage and menopausal status, is an important finding. One could
advocate on the basis of this finding that all patients with early stage breast cancer
should at least receive some form of chemotherapy. Arguments against this policy
have always been based on treatment-related toxicities and the long-term risks of
Improved survival after one course of perioperative chemotherapy in early breast cancer patients
Table 3. Perioperative chemotherapy trials
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developing haematological malignancies after chemotherapy that would not be
counterbalanced by the merits of systemic cytotoxic therapy in node-negative breast
cancer patients. This group of patients, however, is known to have a 70–80% long-term
survival rate after locoregional therapy alone, meaning that 20–30% of these patients
will eventually develop distant metastases and subsequently die of breast cancer. The
argument concerning toxicity may be real in a setting where adjuvant chemotherapy
consists of prolonged schemes like in the National Surgical Adjuvant Breast and
Bowel Project (NSABP) B-13 trial [20]. This trial investigated whether 12 cycles of
methotrexate and 5-fluorouracil followed by leucovorin after surgery would yield
better results than surgery alone in premenopausal, node-negative, ER-negative
patients. In accordance with our results, this trial demonstrated a significant better
disease-free survival rates and better locoregional control in favour of the adjuvant
chemotherapy group. A comparable study conducted by Amadori and colleagues [21]
using CMF showed similar data. In the EORTC trial 10854, only one course of an
anthracycline-containing chemotherapeutic regimen was given. This type of adjuvant
treatment induced a significant improvement in progression-free survival and
locoregional control in the overall analysis, as well as overall survival in a large subset
of patients without intolerable mortality and morbidity [22].
Therefore, one should be aware of these data when developing a treatment strategy
for patients with early stage node-negative breast cancer.
Improved survival after one course of perioperative chemotherapy in early breast cancer patients
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CHAPTER 3
Preoperative Chemotherapy in Primary
Operable Breast Cancer: Results From the
European Organization for Research and
Treatment of Cancer Trial 10902
J.A. VAN DER HAGE, C.J.H. VAN DE VELDE, J-P. JULIEN, M. TUBIANA-HULIN, C. VANDERVELDEN,
L. DUCHATEAU, AND COOPERATING INVESTIGATORS




To evaluate whether preoperative neoadjuvant chemotherapy in patients with primary operable
breast cancer results in better overall survival (OS) and relapse-free survival rates and whether
preoperative chemotherapy permits more breast-conserving surgery procedures than
postoperative chemotherapy.
Patients and Methods: 
Six hundred ninety-eight breast cancer patients (T1c, T2, T3, T4b, N0 to 1, and
M0) were enrolled onto a randomized phase III trial that compared four cycles of fluorouracil,
epirubicin, and cyclophosphamide administered preoperatively versus the same regimen
administered postoperatively (the first cycle administered within 36 hours after surgery). Patients
were followed up for OS, progression free survival (PFS), and locoregional recurrence (LRR).
Results: 
At a median follow-up of 56 months, there was no significant difference in terms of OS (hazards
ratio: 1.16; P = 0.38), PFS (hazards ratio: 1.15; P = 0.27), and time to LRR (hazards ratio: 1.13; P = 0.61).
Fifty-seven patients (23%) were downstaged by the preoperative chemotherapy, whereas 14
patients (18%) underwent mastectomy and not the planned breast-conserving therapy.
Conclusion: 
The use of preoperative chemotherapy yields similar results in terms of PFS, OS, and locoregional
control compared with conventional postoperative chemotherapy. In addition, preoperative
chemotherapy enables more patients to be treated with breast-conserving surgery. Because
preoperative chemotherapy does not improve disease outcome compared with postoperative
chemotherapy, future trials should involve
quality-of-life studies to investigate whether patients will benefit from this treatment modality.
Introduction
Trials that studied the role of adjuvant chemotherapy in the management of primary
operable breast cancer conducted during the 1970s and 1980s showed significant
improvements in progression-free and overall survival [1]. Conventionally, adjuvant
systemic therapy is administered after local treatment in early breast cancer [2].
However, since the introduction of conservative treatment modalities, there has been
considerable interest in the efficacy of preoperative chemotherapy to decrease tumor
size. One of the potential benefits of preoperative chemotherapy is the more frequent
usage of breast-conserving treatment modalities. Moreover, it has been hypothesized
that preoperative chemotherapy has a more powerful effect on survival compared
with postoperative chemotherapy. The rationale for these hypotheses comes from
several biologic premises. Findings in various animal models [3-5] showed an increase
of labeling index in residual tumor cells as well as an increase of circulating 
growth-stimulating factors after the removal of the primary tumor in murine models.
In these models, adjuvant systemic therapy administered before the removal of the
primary tumor impaired this increase in cell-kinetic mechanisms [6,7].
In addition, Goldie and Coldman [8] developed a hypothesis, which implies that as a
tumor cell population increases, an ever-expanding number of drug-resistant
Preoperative Chemotherapy in Primary Operable Breast Cancer
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phenotypic variants arise as a result of spontaneous somatic mutations. Although the
merits of preoperative chemotherapy in the treatment of locally advanced breast
cancer are well established, the feasibility of preoperative chemotherapy in early
breast cancer is still a matter of discussion.
The European Organization for Research and Treatment of Cancer (EORTC) Breast
Cancer Cooperative Group started a randomized trial in 1991 to investigate the value
of preoperative chemotherapy in early breast cancer, EORTC trial 10902. The primary
objective of this trial was to test whether preoperative chemotherapy yields better
results in terms of progression-free and overall survival than the same
chemotherapeutic regimen administered postoperatively. Another objective was to
study whether preoperative chemotherapy would permit more breast-conserving
therapies by reducing primary tumor size. A third objective was to determine whether
preoperative chemotherapy resulted in better locoregional control, especially after
breast-conserving surgery.
An additional objective of the study was to evaluate the response of the primary
tumor to preoperative chemotherapy and to correlate this response to disease-free
and overall survival. This report compares the outcome of 698 women with early




Between April 1991 and May 1999, 698 women were enrolled onto the EORTC study
10902 in 17 institutions in 14 countries. Patients had primary operable breast cancer
(T1c, T2, T3, T4b, N0 to 1, and M0). Breast cancer was preferably diagnosed by core
needle biopsy (CNB) or by fine-needle aspiration cytology as part of triple diagnosis.
For the diagnosis of T1c tumors, CNB was mandatory. CNB was also mandatory in
case of doubt or suspicion of carcinoma-in-situ after fine-needle aspiration. Exclusion
criteria consisted of age older than 70 years; bilateral breast cancer; previous
treatment for breast cancer; presence of distant metastases; pregnancy or lactation at
the time of diagnosis; previous or current other malignancies except adequately
treated basal or squamous carcinoma of the skin or cervix uteri; World Health
Organization performance status more than 2; active cardiac disease; and severe
hematologic, renal, or hepatic abnormalities. All patients gave informed consent
before entering onto the trial. Randomization was performed centrally by the EORTC
Data Center. At randomization, patients were stratified for institution, age (50 years or
50 years), clinical tumor size, clinical nodal status (N or N ), and planned type of
surgery (mastectomy or breast-conserving surgery). Patients 50 years old or younger
were considered to be premenopausal, and those older were deemed
postmenopausal. Tumor estrogen receptor (ER) status was estimated by the ligand
binding assay technique or by the immunohistochemistry technique. For the ligand
binding assay, a concentration ≥ 10 fmol ER/mg protein was considered positive, and a
value lower than 10 fmol ER/mg protein was considered negative. If the ER status was
measured by immunohistochemistry, positivity or negativity was determined
according to the scoring systems used by the individual institutions. There was no
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standardization of the assay, so general cutoff points cannot be given for
immunohistochemistry (EORTC Manual for Clinical Research in Breast Cancer) [9].
Treatment
Treatment consisted of surgery in combination with either preoperative or
postoperative chemotherapy. Surgery consisted of either a modified radical
mastectomy or breast-conserving surgery (wide local excision of the tumor or
quadrantectomy plus axillary dissection and adjuvant radiotherapy). Before
treatment, investigators had to report which type of surgery was indicated at the time
of diagnosis. Subsequently, the planned type of surgery and performed type of
surgery were compared to investigate whether preoperative chemotherapy induced a
higher rate of breast-conserving surgery. Guidelines and selection criteria that
concerned surgery were given in the study protocol, but patient selection for breast-
conserving therapy was ultimately left up to the treating surgeon.
Chemotherapy consisted of four cycles of preoperative fluorouracil 600 mg/m2,
epirubicin 60 mg/m2, and cyclophosphamide 600 mg/m2 (FEC) administered
intravenously, at intervals of every 3 weeks. In the preoperative chemotherapy group,
surgical therapy followed within 4 weeks of the fourth course of chemotherapy. In the
postoperative chemotherapy group, the first cycle was administered within 36 hours
after surgery, as has been advocated before [10,11]. Administration of FEC was 
delayed for a maximum of 2 weeks as a result of either hematologic, hepatic and
renal, or gastrointestinal toxicities on day 1 of any cycle. Dose modifications were
assessed according to the guidelines stipulated by the EORTC Breast Cancer
Cooperative Group [9].
Adjuvant radiotherapy was administered after surgery in the preoperative
chemotherapy group. In the postoperative chemotherapy group, it was decided to
administer irradiation after the completion of chemotherapy. This way, radiotherapy
did not interfere with the chemotherapeutic regimen, in which the first course was to
be administered preoperatively. All patients who underwent breast-conserving
therapy received irradiation of the whole breast. Other recommended guidelines for
radiotherapy, as stipulated in the protocol, consisted of chest wall and parasternal
irradiation in patients with an initial tumor of 5 cm or more in its largest dimension
and irradiation of the infraclavicular and supraclavicular fossa in patients with a
positive infraclavicular node after lymph node dissection. Radiotherapy was indicated
in all cases where surgery was not considered to be radical. Specified dose at the
target volume was 50 gray, administered in four or five weekly fractions in 5 weeks.
For the parasternal/infrasupraclavicular fossa and chest wall, at least 45 Gy had to be
administered in four or five weekly fractions in 4.5 to 5 weeks. However, some
hospitals used their own radiation protocol. Patients ≥ 50 years of age also received
tamoxifen 20 mg daily for at least 2 years, regardless of their ER and nodal status.
End Points
The primary end point of this study was overall survival. Survival time was defined as
the time between randomization and death from any cause. Secondary end points
were progression-free survival and locoregional recurrence. Progression-free survival
was defined as the time between the date of randomization and the date of disease
relapse (including distant metastases, locoregional recurrences, secondary primary
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tumors, and contralateral breast cancers) or death, whichever came first. Locoregional
recurrence was defined as a recurrence in the ipsilateral breast or in the ipsilateral
regional lymph nodes, including supraclavicular nodes. Time to locoregional
recurrence was defined as the time between date of randomization and locoregional
recurrence, regardless of whether the locoregional recurrence was the first event or
not. It is well known that the administration of adjuvant chemotherapy is a
considerable burden to the patient in terms of quality of life. However, not many data
are available that concern the effects of preoperative chemotherapy on quality of life
compared with conventional postoperative chemotherapy. Therefore, a quality-of-life
study program was set up that was, however, unsuccessful as a result of poor
compliance.
Tumor Response
Clinical tumor size and nodal status were estimated before the start of chemotherapy
as well as at the time of surgery by both palpation and mammography. The product of
the two greatest perpendicular diameters was used to compare tumor size before and
after chemotherapy, as defined by the International Union Against Cancer criteria
[12]. A clinical complete response (cCR) was considered a complete disappearance of
all clinically detectable malignant disease by palpation as well as mammography.
Tumor specimens from patients who underwent preoperative chemotherapy were
examined for the presence of microscopic residual tumor to correlate the clinical
absence of tumor with pathologic evaluation. If no signs of residual malignant cells at
the primary site and axillary lymph nodes were seen with histologic examination,
this was scored as a pathologic complete response (pCR). Clinical tumor response to
preoperative chemotherapy was assessed at the time of surgery. If the tumor had
become undetectable before completion of the four cycles of preoperative
chemotherapy, chemotherapy was continued as outlined in the protocol. Clinical
partial response was defined as 50% decrease in total tumor size after four cycles of
preoperative chemotherapy at the time of surgery. An increase of 25% in tumor size
after a minimum of two courses of preoperative chemotherapy was considered to be
progressive disease (PD).
In patients with clinically negative nodes at randomization, the development of
palpable nodes during the administration of preoperative chemotherapy was
considered evidence of PD. After a diagnosis of PD, patients immediately underwent
surgery before completing the preoperative chemotherapy schedule. If the PD was not
primary operable, the patient was declared to have experienced treatment failure, and
subsequent treatment was left to the discretion of the responsible clinician. If
patients did not meet one of the above-mentioned criteria after four cycles of
chemotherapy, they were classified as having stable disease.
Follow-Up
All patients were followed up until death. In the first 2 years after surgery, patients were
seen at least every 6 months and, in the following 3 years, every 6 to 12 months.
Minimal requirements for follow-up were physical examination, locoregional evaluation,
and performance scale assessment, with mammography, chest x-ray, and alkaline
phosphatase and lactate dehydrogenase measurements every year postoperatively. One
institute used CA 15-3 measurements instead of lactate dehydrogenase.
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Statistical Aspects
All analyses were based on the intent-to-treat principle. The two treatment arms
were compared by the log-rank test for the time-to-event end points. The 
differences between the two treatment groups were graphically depicted by Kaplan
and Meier curves. As it seemed from literature studies that both nodal and
menopausal status could have a substantial impact on the treatment comparison, it
was decided before the start of the analysis to perform subgroup analyses for these
two variables. The nominal significance level for each subgroup analysis was adjusted
by the Bonferroni method. Thus, in the cases of the four subgroup analyses for nodal
and menopausal status, the nominal significance level for each of the subgroup
analyses was set at .0125 (.05 divided by 4). The trial was designed to detect a 10%




Of the 698 patients, 350 patients were randomized to receive preoperative
chemotherapy, and 348 patients were randomized to the postoperative chemotherapy
group (first cycle of FEC administered within 36 hours after surgery). Tumor and
patient characteristics were well distributed between the two treatment arms 
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(Table 1), except for breast-conserving
surgery rates, which were, as
expected, higher in the preoperative
chemotherapy group. Twenty-one
patients were considered ineligible
because of inadequate staging (n = 17),
a World Health Organization perfor-
mance status more than 2 (n = 3), or
age greater than 70 years (n = 1).
Chemotherapy
Overall, 635 patients (91%) received
the planned chemotherapy dose (321
patients [92%] in the study arm and
314 patients [90%] in the control arm).
Sixty-three patients (8%) received less
than 75% of the planned dose.
Nineteen patients (3%) who began
chemotherapy did not complete it (11
patients [3%] in the study arm and
eight patients [2.5%] in the control
group). Thirty-eight patients who were
randomized to the preoperative
chemotherapy group underwent
treatment modification because of
treatment-related febrile neutropenia
versus 44 patients in the postoperative
chemotherapy group. No treatment-
related deaths were reported. An
overview of chemotherapy-related
toxicity is given in Table 2.
Furthermore, four patients who were
randomized to receive postoperative
chemotherapy received preoperative
chemotherapy, and three patients who
were randomized to receive
preoperative chemotherapy received postoperative chemotherapy. Forty patients did
not receive chemotherapy. Of these patients, 16 patients were deemed ineligible. Eight
patients refused chemotherapeutic treatment, two patients in the postoperative
chemotherapy group did not receive chemotherapy as stipulated by the protocol
because of postoperative complications, and seven patients did not receive
chemotherapy for unknown reasons. From a further seven patients, no information
that concerned treatment specifications or follow-up was received, even after
repeated queries. Unfortunately, for approximately 30% of the patients, information
that concerned ER status was missing. This was partly a result of the fact that this
information was not mandatory and that tamoxifen was given irrespective of ER
status in patients ≥ 50 years of age.
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Surgery
Four hundred sixty-five patients
underwent modified radical mastectomy,
and 199 patients underwent breast-
conserving surgery. Nineteen patients
who underwent lumpectomy did not
receive adjuvant radiotherapy. Thirty-
eight percent of the patients on the study
arm who were treated with mastectomy
received radiotherapy, and 43% of the
patients on the control arm who were
treated with mastectomy received
radiotherapy.
In the preoperative chemotherapy group,
20 patients did not receive the surgical
treatment stipulated by the study
protocol, versus 14 patients in the
postoperative group. At the time of
axillary clearance, at least six nodes had
to be obtained for pathologic
examination, and in 77% of the patients
entered onto the study, 10 or more
axillary nodes were examined. Surgical
complications consisted of 16 grade 1/2
wound infections in the preoperative
chemotherapy group, versus 25 grade 1/2
wound infections and two grade 3/4
wound infections in the postoperative
chemotherapy group that required
antibiotic treatment. Anticoagulant
prophylaxis was administered on the
basis of experience from previous trials
that studied the efficacy of perioperative
chemotherapy [13,14]. No severe
postsurgical thromboembolic
complications were observed in the
postoperative chemotherapy group.
Overall Survival, Progression-Free Survival,
and Locoregional Recurrence
Of the 698 randomized patients, 232
experienced relapse, from which 124
patients died. Furthermore, 10 patients
died without experiencing a relapse. No
significant differences between the two
treatment arms were observed for
progression-free and overall survival.
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Overall survival after 4 years was 82% in
the preoperative group and 84% in the
postoperative group (hazards ratio [HR],
1.16; 95% confidence interval [CI], 0.83 to
.63; P = 0.38) (Fig 1). Progression-free
survival rates after 4 years for the
preoperative and postoperative groups
were 65% and 70%, respectively (HR, 1.15;
95% CI, 0.89 to 1.48; P = 0.27) (Fig 2). To
date, 69 patients have experienced a
locoregional recurrence, 36 in the
preoperative chemotherapy group and 33
in the postoperative chemotherapy group.
Time to locoregional recurrence was not
significantly different between the two
treatment arms (HR, 1.13; 95% CI, 0.70 to
1.81; P = 0.61) (Fig 3). Sixty-two of these
patients experienced a locoregional
recurrence as first event. Subgroup
analyses were performed in an
exploratory way for nodal status and menopausal status. The largest difference was
found in clinical node-negative patients (n  = 385) in terms of overall survival (HR, 1.77;
95% CI, 1.03 to 3.02; P = 0.04) and progression-free survival (HR, 1.53; 95% CI, 1.03 to
2.28; P = 0.03) in favor of the postoperative chemotherapy group. These P values failed
to be significant compared with the adjusted nominal significance level of 0.0125.
Tumor Response
Table 3 shows the clinical tumor response after chemotherapy. An overall objective
response was observed in 49% of the patients randomized to the preoperative
chemotherapy group. Twenty-three patients (6.6%) experienced a cCR and progression
of disease was seen in five patients (1.4%). Of the twenty-three patients who
experienced a cCR, only six patients did not have any invasive tumor left. Apart from
the six patients who experienced a pCR in accordance with the clinical assessment,
seven other patients were microscopically free of tumor at the primary site and axilla
after four cycles of preoperative chemotherapy but were not classified as having a
cCR. The thirteen patients without evidence of residual malignancy do have a
significant advantage in terms of overall survival (HR, 0.86; 95% CI, 0.77 to 0.96; 
P = 0.008) compared with patients who still had residual tumor cells left after
preoperative chemotherapy.
Next, we tested the prognostic significance of clinical objective tumor response in
terms of survival in a multivariate model together with clinical tumor size, clinical
nodalstatus, and ER status. Clinical objective response, however, was not a significant
prognostic factor. Table 4 shows the correlation between clinical tumor sizebefore
preoperative chemotherapy and pathologic tumor size after preoperative
chemotherapy. Both in the preoperative and postoperative arms, 14% of the patients
had a clinical tumor size less than 2 cm at the time of diagnosis. After four courses of
preoperative chemotherapy, 47% of the patients had a pathologic tumor size less than
Preoperative Chemotherapy in Primary Operable Breast Cancer
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Table 4. Clinical tumor size vs. pathological
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2 cm, whereas 26% of the patients in the
postoperative arm had a pathologic
tumor size less than 2 cm. Nodal status
characteristics are listed in Table 5. At the
time of diagnosis, 49% of the patients in
the preoperative group and 47% of the
patients in the postoperative group had
clinical negative axillary lymph nodes.
Pathologic examination after surgery
showed a lower percentage of negative
axillary lymph nodes in both the
preoperative and the postoperative group
38% and 35%, respectively. Differences in
pathologic tumor size and axillary nodal
status between both study arms are listed
in Table 6 and Table 7.
Downstaging
Before treatment, investigators had to
report whether mastectomy or breast-
conserving surgery was indicated. In the
preoperative chemotherapy group, the
rate of  breast-conserving therapy was
higher than in the postoperative
chemotherapy group. In the preoperative
chemotherapy group, 57 patients (23%)
underwent breast-conserving surgery and
not the planned mastectomy (Table 8),
versus 14 patients (18%) who underwent
mastectomy and not the planned breast-
conserving surgery.
In the preoperative chemotherapy group,
all patients who underwent breast-
conserving surgery were compared
according to their planned type of
surgery. Patients who were planned for
mastectomy but underwent breast-
conserving therapy because of down-
staging of the tumor did worse in terms of overall survival (HR, 2.53; 95% CI, 1.02 to
6.25)  compared with patients who were initially planned to receive breast-conserving
therapy and were treated accordingly (Fig 4), which suggested a relation between the
outcome of locoregional treatment and tumor response. This, however, is not a
randomized comparison. The observed difference in disease outcome might be a
result of a selection bias as a result of different patient characteristics in the two
groups. Therefore, we evaluated patient characteristics to detect potential differences.
Of the patients who were downstaged, 35% were clinically node-negative before the
start of chemotherapy versus 46% in the group in which breast-conserving therapy
Preoperative Chemotherapy in Primary Operable Breast Cancer
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Table 7. Differences in pathological nodal
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Table 5. Clinical nodal status vs. pathological
nodal status after pre-operative chemotherapy
Table 8. Planned versus performed type of
surgery
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was already indicated before the
administration of chemotherapy. After
chemotherapy, the pathologic node-
negative rates were 63% and 51%,
respectively. This indicates that axillary
nodal response to preoperative
chemotherapy was actually better in
downstaged patients than in the others
who underwent breast-conserving
surgery. Remarkably, there was an
obvious similarity in both clinical tumor
size before preoperative chemotherapy
and pathologic tumor size between the
two groups (Table 9). These differences
may well be a result of differences in
initial tumor-node-metastasis system
classification between both of these
patient groups. However, the fact that
clinical T and N stages were to a large
extent similar does not support this
hypothesis. Conclusively, these findings
do support the assumption that radical
conservative surgery, especially after
downstaging, may be more difficult
because of the fact that tumor-free
margins are more difficult to assess after
preoperative chemotherapy.
Quality of Life
Unfortunately, only one institution has
collected quality-of-life data on a total
number of 20 patients. These data are
insufficient to report here or to draw any
conclusion on the effect of preoperative
chemotherapy on quality of life.
Discussion
In 1986, the Breast Cancer Cooperative
Group started a trial to study the
effectiveness of one course of
fluorouracil, doxorubicin, and cyclophosphamide administered perioperatively within
36 hours after surgery in early breast cancer patients. This regimen resulted in
significantly improved locoregional control and disease-free survival rates [10].
Therefore, the logical next step was to start a trial that would study the qualities of
preoperative chemotherapy.
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Figure 4. Survival in planned versus
downstaged mastectomy
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EORTC trial 10902 was designed to address whether preoperative chemotherapy
yields the same or better results in terms of overall and disease-free survival
compared with the same type of chemotherapy administered postoperatively and
whether preoperative chemotherapy allows more breast-conserving therapies. A third
objective was to assess the value of tumor response to preoperative chemotherapy as
a predictor of disease outcome. Several randomized, clinical, phase III trials that
compared postoperative adjuvant chemotherapy and preoperative chemotherapy
were performed in the past two and a half decades. These trials have been listed in
Tables 10 to 12. A comparison of the results of these trials is difficult because of the
fact that the study protocols differ substantially in design and chemotherapeutic
regimen. However, to date none of these trials, including EORTC trial 10902, has been
able to show a positive effect of preoperative chemotherapy in terms of progression-
free or overall survival.
Two trials, conducted by Mauriac and Scholl [15-20] initially reported a significant
positive effect of preoperative chemotherapy on progression-free and overall survival,
but after a longer period of follow-up, the significant benefit of preoperative
chemotherapy on survival had disappeared. In addition, in the Mauriac trial,
locoregional control was worse in the preoperative arm compared with the standard
arm. Of the trials listed in Tables 10 through 12, the National Surgical Adjuvant Breast
and Bowel Project B-18 [21,22 ] trial is similar in terms of study design to the EORTC
trial. Fisher et al [21,22] studied the efficacy of four courses of preoperative
doxorubicin and cyclophosphamide in 1,523 women with primary operable breast
cancer. Contrary to the EORTC trial, the first course of postoperative chemotherapy
was not administered directly after surgery. Overall survival, progression-free
survival, and recurrence rates were not significantly different between the study and
the postoperative population. Interestingly, the authors observed a significantly
higher rate of ipsilateral breast recurrences in patients who underwent a lumpectomy
as a result of downstaging compared with the rate in patients who underwent a
lumpectomy as planned. We observed a similar effect on overall survival in patients
who underwent breast-conserving surgery as a result of downstaging. However, we
did not find such an effect on locoregional recurrence rates. Nevertheless, these
results demonstrate an important potential danger induced by tumor downstaging.
Even if clinical assessment of tumor response demonstrates tumor shrinkage as a
result of chemotherapy, there is no absolute proof that the tumor has actually
shrunken in size. Several authors demonstrated a loss of density in tumors treated by
chemotherapy but no shrinkage [23-25]. In our trial, the mammographies before and
after preoperative chemotherapy of 83 patients were revised and correlated with
histologic data, and a similar effect on the assessment of tumor response was found
(data not shown). Thus, treating downstaged tumors with more breast-conserving
modalities may result in a higher false-negative rate of tumor-negative surgical
margins. In the B18 trial, a clinical overall response was seen in 79%, whereas 35% of
the preoperative chemotherapy group experienced a cCR. A pCR, however, occurred in
only 9% of these patients. Disease-free, relapse-free, distant disease-free, and overall
survival were better in women whose tumors showed a pCR compared with those
patients with residual disease. This is in accordance with the results from the EORTC
10902 study and the experience of other investigators [19,26].
In the EORTC trial, tumor response to preoperative chemotherapy was low in
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comparison with the response rates described in the literature [15-22,26-36]. Clinical
overall tumor responses after four to six cycles of preoperative polychemotherapy
range approximately between 65% and 90%. The cCR rates vary between 10% and 30%.
However, the pCR rate usually is much lower, resulting in a poor correlation.
Controversially, in the EORTC 10902, trial 49% of the patients who received
preoperative chemotherapy experienced a clinical overall response as assessed by
palpation and 7% of the study-population had a cCR. The remarkable discrepancy
between our results and those of other authors is difficult to explain. The vast
majority of patients received the chemotherapeutic dose stipulated by the protocol,
ie, four courses of FEC containing epirubicin 60 mg/m2, which means that the
regimen was well tolerated. Now, one could argue that total cumulative doses of
epirubicin lower than 300 mg/m2 are suboptimal. However, higher doses of epirubicin
in a combined chemotherapy schedule have so far not been demonstrated to be more
effective in terms of overall or relapse-free survival in primary operable breast cancer
[37-40]. Several studies [23-25] have addressed this discrepancy between cCR and pCR
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and compared clinical measurements with mammographic and ultrasonographic
measurements. These studies generally demonstrate an overestimation of tumor
response by palpation alone. In the majority of clinical trials that study the effects of
preoperative chemotherapy, clinical measurements are commonly used to assess the
amount of tumor response, as described by the guidelines of the International Union
Against Cancer. In EORTC trial 10902, tumor response was measured by using the
data of both palpation and mammographic tumor measurements. Unfortunately, we
were not able to demonstrate this confounding error induced by using palpation
measurements alone because of a poor registration of measurements. Conclusively,
mammographic measurements should be implemented in the assessment of tumor
response on a standard basis to give an objective idea of the degree of tumor
response. Moreover, in the case of a cCR, it may be helpful to perform ultrasono-
graphy in selecting those patients who do not require surgery after preoperative
chemotherapy and in localizing abnormalities in those who do [41,42].
In locally advanced and primary inoperable breast cancer, the purpose of preoperative
treatment is to enable adequate local treatment, favorably leading to breast
conservation. In patients with stage I or II breast cancer who are candidates for
breast-conserving therapy irrespective of preoperative chemotherapy, the goal of
preoperative chemotherapy is unclear. Some investigators argue that tumor response
to preoperative chemotherapy is an independent predictor of treatment outcome.
Therefore, it could be of benefit for breast cancer patients to adjust systemic adjuvant
treatment at an early stage if tumor response to preoperative chemotherapy is
inadequate.
Controversially, preoperative chemotherapy might lead to overtreatment of breast
cancer patients. This can be explained by the fact that patients receive systemic
treatment regardless of histologic staging of the tumor and axillary nodal status. The
breast-conserving therapy rate was higher in the preoperative chemotherapy group in
comparison with the postoperative chemotherapy group. This finding, together with
the equal locoregional control rate in both groups, advocates the advantageous role of
primary chemotherapy in breast-conserving management. On the other hand, 14% of
patients who initially were supposed to undergo breast-conserving surgery received a
modified radical mastectomy. This suggests that a delay in surgical treatment as a
result of the use of primary chemotherapy can result in a more aggressive type of
surgical management of breast cancer in a considerable number of patients. In
addition, a hypothesis-generating analysis that compared survival rates of patients
who underwent breast-conserving surgery as a result of downstaging of the tumor
with patients who underwent breast-conserving surgery as initially was planned
showed a favorable trend for the latter group of patients. Therefore, it can be
hypothesized that patient prognosis is determined by the initial tumor stage and not
tumor stage after preoperative chemotherapy.
The idea that changes in surgical management after preoperative chemotherapy are
solely because of either increase or decrease of tumor volume is arguable. Because
preoperative chemotherapeutic regimens take approximately 3 months to complete,
patient or doctor surgical preferences may be altered for subjective reasons during
this period of time.
The use of preoperative or primary chemotherapy was introduced approximately
three decades ago in locally advanced breast cancer. Since then, its role in the
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management of locally advanced breast cancer has been firmly established. However,
the advantages are not clear in early breast cancer. Despite the fact that preoperative
chemotherapy may permit more breast-conserving treatment modalities, there may
be problems, for instance in achieving adequate locoregional control as a result of the
difficulty of assessing tumor margins after the administration of preoperative
chemotherapy.
Moreover, it has become clear that the supposed survival benefits of preoperative
chemotherapy based on preclinical data are not exerted in primary operable breast
cancer patients. Although benefits of preoperative chemotherapy in early breast
cancer patients are less clear compared with the locally advanced breast cancer
patients, the potential to enhance breast-conserving therapy makes it an attractive
treatment modality. Postmenopausal early breast cancer patients especially might
benefit from preoperative chemotherapy, although preoperative chemotherapy may
be less beneficial for young breast cancer patients who are at a higher risk of
recurrence of disease, especially after primary conservative therapy. Although this
trial did not show such differences (data not shown), other investigators have found
young age to be a strong independent prognostic factor for recurrence after breast-
conserving therapy [11,43,44].
Moreover, the possibility of studying the effects of chemotherapy on well-established
tumor characteristics as well as experimental tumor markers makes chemotherapy in
the preoperative setting highly attractive for translational research purposes [45]. The
comparison of core needle biopsies with the same tumor after systemic treatment is
a worthwhile reason to continue preoperative chemotherapy trials in early breast
cancer.
Unfortunately, not many data concerning quality-of-life issues in relation to
preoperative chemotherapy are available in the literature. Quality-of-life studies,
however, have been performed to investigate the effects of breast-conserving therapy
versus mastectomy and fail to show a clear benefit for the conservative treatment
modality, except for a slightly less impaired body image [46-49]. Considering the fact
that preoperative as well as postoperative chemotherapy seems to yield similar
results in terms of prognosis, this might be a conclusive factor on the decision of
which chemotherapeutic strategy should be chosen. Therefore, the role of
preoperative chemotherapy should be studied in future trials that focus on
translational research, equivalence, quality of life, and local control, rather than trying
to detect overall and progression-free survival differences.
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CHAPTER 4
Pathological complete response to 
preoperative anthracycline-based chemotherapy
in operable breast cancer: the predictive role of
p53 expression
J. S.D. MIEOG, J.A. VAN DER HAGE, M.J. VAN DE VIJVER, C.J.H. VAN DE VELDE,
AND COOPERATING INVESTIGATORS OF THE EORTC.
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Abstract 
The aim of this retrospective study was to identify markers capable of predicting pathological
complete (pCR) and overall clinical tumour response to preoperative anthracycline-based
chemotherapy and clinical outcome in women with operable breast cancer.Therefore, we used the
pre-treatment core biopsies from 107 patients who were enrolled in the EORTC trial 10902 to
analyse tumour characteristics and the oncogenic markers bcl-2, p53, ER, PgR, HER2, and p21.
Median follow-up was 7 years (95% confidence interval [CI], 6.89-7.45). pCR was seen in seven
patients (6.5%) and was associated with improved overall survival (hazards ratio, 0.39; 95% CI, 0.05-
2.56; P = 0.30). In multivariate logistic regression analysis, pCR was independently predicted by p53
overexpression estimated by immunohistochemistery (odds ratio [OR], 16.83; 95% CI, 1.78-159.33;
P = 0.01). Fifty-eight patients showed clinical tumour response (>50% decrease in tumour size),
however responders experienced no benefit in clinical outcome. Clinical tumour response was
independently predicted by p53 overexpression (OR, 5.57; 95% CI, 1.58-19.65; P = 0.008) and small
clinical tumour size (OR, 10.26; 95% CI, 2.01-52.48; P= 0.005). In multivariate Cox regression
analysis, negative pathological lymph node status, low tumour grade and use of tamoxifen
showed improved overall survival. In conclusion, our data suggest p53 expression is of predictive
significance in anthracycline containing chemotherapeutic regimens.
Introduction
Preoperative chemotherapy for large but early stage breast cancer has been subject of
interest for over two decades. The efficacy of preoperative chemotherapy has been
demonstrated in several prospective randomized trials showing similar survival and
locoregional control rates in patients receiving preoperative chemotherapy and
postoperative chemotherapy. Tumour downstaging due to preoperative chemotherapy
was found to increase breast-conserving therapy rates [1,2].
Response of breast tumours following preoperative chemotherapy can be assessed
either clinically or pathologically. Patients with responding tumours showed an
improved overall and disease-free survival and particularly pathological complete
response (complete disappearance of malignant cells on microscopic examination;
pCR) is suggested as a surrogate marker for these clinical endpoints [2-5].
Translational research using preoperative tumour tissue biopsies is an excellent study
model to analyse the predictive value of different tumour characteristics for response
to chemotherapy [6]. To date, a large number of oncogenic markers in breast cancer
have been studied using classical survival analyses [7,8]. However, published data on
the relation between tumour characteristics and pathological and clinical tumour
response are still limited.
We used data from a prospective randomized trial comparing pre- versus
postoperative chemotherapy to study the correlation between pathological and
clinical tumour response and patient and tumour characteristics. Tumour
characteristics included oncogenic markers analysed on pre-treatment biopsy
specimens and classic tumour characteristics. In addition, we assessed the prognostic
significance of these clinical characteristics including pathological and clinical
tumour response on overall and distant disease-free survival.
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All patients participated in a prospectively randomized trial (EORTC 10902) that
compared preoperative chemotherapy versus the same chemotherapeutic regimen
administered postoperatively in patients with operable breast cancer [1]. This trial
accrued 698 women with early stage breast cancer between 1991 and 1999. The
eligibility criteria for this trial have been described previously [1]. Efforts were made
to obtain diagnostic biopsy material from all patients randomized to preoperative
chemotherapy. For the present analysis we included patients who had received
preoperative chemotherapy with known pathological and clinical tumour response
and from whom biopsy material were available for pathological evaluation. We used
pre-treatment biopsy material for immunohistochemical analyses in order to avoid
interference of the chemotherapeutic regime on the expression levels of the
oncogenic markers [9,10].
Treatment
Chemotherapy consisted of four cycles of preoperative fluorouracil 600 mg/m2,
epirubicin 60 mg/m2, and cyclophosphamide 600 mg/m2 (FEC) administered
intravenously, at intervals of every 3 weeks. Surgical therapy followed within 4 weeks
of the fourth course of chemotherapy. Surgery consisted of either a modified radical
mastectomy or breast-conserving surgery (wide local excision of the tumour or
quadrantectomy plus axillary dissection and adjuvant radiotherapy). Recommended
guidelines for radiotherapy have been described previously [1]. If radiotherapy was
indicated, it was administered after surgery. Patients older than 50 years also received
tamoxifen 20 mg daily for at least 2 years, regardless of their oestrogen receptor and
nodal status.
Pathological tumour response
Surgical tumour specimens were examined for the presence of microscopic residual
tumour. If no signs of residual malignant cells at the primary site were seen with
histological examination, this was scored as a pathological complete response (pCR).
The specimens still containing invasive malignant cells were graded as pINV.
Clinical tumour response 
The tumour response classification system used in EORTC 10902 was according to the
UICC [11]. Clinical tumour size was scored by the local investigators before the start of
chemotherapy as well as at the time of surgery by both clinical examination and
mammography. The product of the two greatest perpendicular diameters was used to
compare tumour size before and after chemotherapy.
Clinical complete response (cCR) was defined as complete disappearance of all
clinically detectable malignant disease by palpation and mammography. Clinical
partial response (cPR) was defined as ≥ 50% decrease in total tumour size after four
cycles of preoperative chemotherapy. An increase of ≥ 25% in tumour size after a
minimum of two courses of preoperative chemotherapy was considered to be
progressive disease (cPD). If patients did not meet one of the above-mentioned
criteria after four cycles of chemotherapy, they were classified as having stable
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disease (cSD). For the purpose of this analysis, we distinguished between patients
with overall clinical response (cCR and cPR) and patients with non-responding
tumours (cSD and cPD).
Histology and immunohistochemistery
Blocks were collected from core needle biopsies taken before the start of chemotherapy.
All immunohistochemical (IHC) analyses were performed in one reference laboratory by
two pathologists who were unaware of the clinical outcome of the patients.
Invasive carcinomas were histologically graded according to the method of Bloom and
Richardson, adapted by Elston and Ellis [12]. BCL-2 was assessed using Clone 124
(Boehringer Mannheim, Germany) and scored according to van Slooten and
colleagues (staining ≥ 3 indicates positive status) [13]. P53 accumulation was detected
using Do-7 monoclonal antibody (NovaCastra, Newcastle on Tyne, United Kingdom)
and a semi-quantitative system based on the sum of the mean staining intensity (0 to
3; none to strong) and an estimation of the percentage of positive cell nuclei (0 to 4;
0% to > 75%); this allowed a sum score of 0 to 7, with staining ≥ 4 being considered
positive [14]. Oestrogen receptor status (ER) was estimated immunohistochemically
using the monoclonal antibody DAKO-ER 1D5 (Dako, Glostrup, Denmark; staining
indicates positive status) [14]. Progesterone receptor status (PgR) was measured using
mPRI monoclonal antibody (Transbio, Paris, France; staining indicates positive status)
[14]. HER2 expression was assessed using the monoclonal antibody 3B5 (staining score
0, 1 and 2 indicates a negative result and ≥ 3 resembles a positive result) [15]. P21 was
measured using the monoclonal antibody EA10 (Calbiochem, Cambridge, MA, USA; ≥ 3
indicates a positive result) [13,14].
Statistical Methods
Overall survival time was defined as the time between randomization and death from
any cause. Distant disease-free survival was defined as the time between the date of
randomization and the date of distant disease relapse or death from any cause
whichever came first. Correlations between the two tumour response classification
systems and patient and tumour characteristics were tested using the Pearson’s 
Chi-square test or the Fisher’s Exact test. A multivariate logistic regression model was
fitted that was based on all characteristics that had a P value up to 0.10 in the
univariate analysis. The effect of patient and tumour characteristics on the survival
endpoints was assessed using the Cox proportional hazards regression model to
estimate hazard ratios and their 95% confidence intervals. A multivariate Cox
regression model was fitted that was based on all characteristics that had a P value
up to 0.10 in the univariate analysis. Survival curves of the tumour response groups
were estimated using the Kaplan-Meier technique. The statistical analyses were
performed using SPSS software (SPSS Inc., Chicago, II, USA). A two-sided significance
level of 0.05 was used.
Results
Patient and tumour characteristics
EORTC 10902 trial randomised 350 patients to preoperative chemotherapy and 321
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patients received this allocated treatment. Tumour response was assessable in 301
patients. For 194 of these patients no data was available on histological and
immunohistochemical analyses. Thus, we were able to include 107 patients in this
study. Patient and tumour characteristics are listed in Table 1.
The median age at diagnosis was 49.8 years. Seven (6.5%) pathological complete
responses following preoperative chemotherapy were seen and 58 (54%) patients had
clinically responding tumours. All but one of the patients with pCR were clinically
graded as responders. At the time of analysis, the median follow-up period was seven
years (95% confidence interval [CI], 6.89-7.45); thirty-one (29%) patients have died and
of the patients alive, ten (9.3%) have experienced a distant relapse. Although
otherwise stipulated in the treatment protocol, nine (17%) women older than 50 years
were not administered to tamoxifen treatment and four (7.4%) women in the younger
group did use tamoxifen.
Prognostic value of pathological tumour response 
The association of pathological tumour response with overall survival and distant
disease-free survival is shown in Figure 1 and 2, respectively. Patients with complete
pathological response had an overall survival rate after 7 years of 86% compared with
68% for patients with residual disease (pINV) on pathological examination (hazards
ratio [HR], 2.87; 95% CI, 0.39-21.14; P = 0.30). Patients with a complete pathological
response had a distant disease-free survival rate at 7 years follow-up of 86%,
compared to 59% for patients with pINV (HR, 3.62; 95% CI, 0.50-26.33; P = 0.21).
Prognostic value of clinical tumour response 
Patients with a clinical tumour response had an overall survival rate after 7 years of
67% (Figure 3). Non-responders had an overall survival rate of 75% (HR, 0.71; 95% CI,
0.34-1.45; P = 0.35). Patients with clinical response had a distant disease-free survival
rate after 7 years of 61% compared to 61% for patients with non-responding tumours
(HR, 0.94; 95% CI, 0.51-1.74; P = 0.84; Figure 4).
Predictive characteristics for pathological and clinical response
We assessed the predictive value of patient and tumour characteristics and
expression of oncogenic markers in pre-treatment core needle biopsies.
Table 2 lists the relationships between dichotomized characteristics and pathological
and clinical tumour response. Pathological lymph node status and p53 status were
significantly correlated with pathological tumour response. Including both variables
in the multivariate analysis (Table 3) revealed an independent relationship of positive
p53 expression with pCR (odds ratio [OR], 16.83; 95% CI, 1.78-159.33; P = 0.01) and a
non-significant association of negative pathological lymph node status. Clinical
tumour response was predicted by clinical tumour size, tumour grade, p53 status, PgR
status, and HER2 status (Table 2). In multivariate analysis, positive p53 expression (OR,
5.57; 95% CI, 1.58-19.65; P = 0.008) and small clinical tumour size (OR, 10.26; 95% CI,
2.01-52.48; P = 0.005) remained as independent predictive factors of clinical tumour
response (Table 3).
Prognostic characteristics for overall survival and distant disease-free survival 
Table 4 shows the prognostic value of patient and tumour characteristics in
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predicting clinical outcome. In this univariate analyses, significant prognostic
variables for overall and distant disease-free survival were age, use of tamoxifen, and
pathological lymph node status. In addition, histological tumour grade was
significantly associated with overall survival. Overexpression of p53 was non-
significantly related with poorer overall (HR, 1.72; 95% CI, 0.82-3.62; P = 0.15) and
distant disease-free survival (HR, 1.39; 95% CI, 0.70-2.74; P = 0.35).
The prognostic factors found to be trend significant in the univariate analyses were
included in multivariate analyses to identify independent prognostic factors of overall
and distant disease-free survival (Table 5). Negative pathological lymph node status
and use of tamoxifen were both independently associated with improved overall and
distant disease-free survival. In addition, histological tumour grade III was an
independent prognostic factor of poorer overall survival.
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Figure 3. Clinical tumor response and overall
survival
Figure 4. Clinical tumor response and distant
disease-free survival
Figure 1. Pathological tumour response and
overall survival.
pCR= pathological complete response; 
pINV= invasive tumour cells on pathological
examination
Figure 2. Pathological tumour response and
distant disease-free survival.
pCR= pathological complete response; 
pINV= invasive tumour cells on pathological
examination 
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Discussion




and pathological complete and
clinical tumour response to 
4 cycles of preoperative FEC.
However, pCR as a prognostic
factor for overall survival as
well as for distant disease-free
survival did in this patient
population not reach
statistical significance
although a clear trend was
demonstrated (Figures 1 and





operable breast cancer while
pCR was in these studies a
significant prognostic factor 
[2, 16-18].
In this study, clinical tumour
response showed no
prognostic benefit (Figures 3
and 4). This result is in
discordance with other reports
[2,16,17] and most probably
resembles a selection bias as
the data derived from our
larger study population
suggest an association of non-
response with poorer overall
survival (HR, 1.43; 95% CI, 0.91-
2.24; P = 0.12). However, the
fact that clinical responders in
the current group had no
favourable prognosis implies
that the results concerning the
predictive value of
characteristics for clinical
response must be interpreted
with caution. Moreover,
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Table 2. Pathological and clinical tumour response and
dichotomized patient and tumour characteristics
Table 3. Multivariate logistic regression analyses of
correlation between dichotomized tumour characteristics
and pathological complete tumour response (N=99) and
clinical response (N=94)
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Table 4. Univariate Cox regression analyses of characteristics predicting for overall
and distant disease-free survival




chemotherapy is difficult and
can be either under- or
overestimated due to fibrosis,
weakening of the tumour





Although pCR in our study was
associated with p53
overexpression and higher survival rate, positive p53 status was not translated in
improved clinical outcome. In contrast, p53 overexpression was non-significantly
related with poorer overall and distant disease-free survival. Hypothetically, the
short-lived benefits of better response of p53 positive tumours may be overcast by
rapid regrowth of micro-metastases after initial remission of the primary tumour,
reflecting their aggressive biology. Though, analysis of this hypothesis that survival in
the pCR subgroup is dependent on p53 status was not possible due to the limited
power of the current study.
P53, a nuclear protein, plays an essential role in the regulation of cell cycle and
functions as a tumour suppressor. Breast cancer patients with p53 mutations or
protein accumulation measured by IHC in their tumours have worse survival [23-26].
Meanwhile, the literature of the predictive value of p53 status on tumour response to
preoperative anthracycline-based chemotherapy is conflicting.(7) Most studies find no
association between p53 expression and tumour response to anthracyclines [27-32].
Others have associated p53 overexpression with both resistance [14, 33-35] and
sensitivity [10,36] to preoperative anthracycline containing chemotherapy.
Interpretation of the above literature is complicated since the definition of response
various across studies, the correlation between p53 protein accumulation and the
presence of mutations is not absolute and numerous non-standardized IHC
techniques have been used, limiting the possibility to draw valid conclusions [37].
The pathological lymph node status after preoperative chemotherapy is in our data
an independent prognostic factor for both overall and distant disease-free survival.
This finding is confirmed by others [3, 38-40]. However, the pre-treatment clinical
lymph node status was poorly correlated with clinical outcome. At the time this trial
was conducted, the pre-treatment nodal status was determined by palpation.
Nowadays, imaging techniques such as ultrasound are more feasible in establishing
nodal status [41]. Future trials should include this technique to provide more reliable
information of the actual response of lymph node metastases to preoperative
chemotherapy and to determine the subsequent prognostic significance of such a
response.
At this time, it is not possible to select patient who will benefit from chemotherapy.
However, data have begun to emerge from micro-array studies which may lead to the
introduction of tailored treatment strategies based upon custom made risk profiles
rather than the classic guidelines derived from traditional RCT’s [42-45].
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Table 5. Multivariate Cox regression analyses of
characteristics predicting for overall (N=101) and distant
disease-free survival (N=107)
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In conclusion, our data derived from a prospective randomized trial suggest that p53
overexpression estimated by immunohistochemistery is an independent predictive
factor of tumour response after preoperative anthracycline-based chemotherapy in
operable breast cancer patients. However, this conclusion must be limited to the
regime used in this trial (FE60C) which is probably suboptimal today [46]. Moreover,
the relatively small sample size requires conformation in larger studies and the use
of p53 measurements should be restricted to clinical trial settings. Prospectively
derived data on the predictive and prognostic value of p53 is on the way from the
neoadjuvant EORTC trial 10994 [47,48].
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CHAPTER 5
Overexpression of P70 S6 kinase protein is
associated with increased risk of locoregional
recurrence in node-negative premenopausal 
early breast cancer patients
J.A. VAN DER HAGE, L.J.C.M. VAN DEN BROEK, C. LEGRAND3, P.C. CLAHSEN, C.J.A. BOSCH,
E.C. ROBANUS-MAANDAG, C.J.H. VAN DE VELDE AND M.J. VAN DE VIJVER
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Abstract
The RPS6KB1 gene is amplified and overexpressed in approximately 10% of breast carcinomas and
has been found associated with poor prognosis. We studied the prognostic significance of P70 S6
kinase protein (PS6K) overexpression in a series of 452 node-negative premenopausal early-stage
breast cancer patients (median follow-up: 10.8 years). Immunohistochemistry was used to assess
PS6K expression in the primary tumour, which had previously been analysed for a panel of
established prognostic factors in breast cancer. In a univariate analysis, PS6K overexpression was
associated with worse distant disease-free survival as well as impaired locoregional control (HR
1.80, P = 0.025 and HR 2.50, P = 0.006, respectively). In a multivariate analysis including other
prognostic factors, PS6K overexpression remained an independent predictor for poor locoregional
control (RR 2.67, P = 0.003). To our knowledge, P70 S6 kinase protein is the first oncogenic marker
that has prognostic impact on locoregional control and therefore may have clinical implications
in determining the local treatment strategy in early-stage breast cancer patients.
Introduction
The treatment of breast cancer is guided by risk factors. Approximately 70% of all
node-negative breast cancer patients can be cured by locoregional therapy alone. This
automatically implies that the remaining 30% of these patients will develop a
recurrence despite adequate locoregional therapy. Currently, treatment strategy in
breast cancer is based upon tumour stage, grade, and hormone receptor status.
Additional prognostic factors are greatly needed, first to select those patients who
might benefit from adjuvant systemic therapy and second to optimise locoregional
therapy in order to avoid   locoregional recurrences.
The prognostic significance of a considerable number of tumour markers has already
been investigated but to date, none of these factors can be used to guide the
treatment of primary breast cancer.
A recent study by Barlund et al [1] demonstrated that amplification of a putative
tumour marker called P70 S6 kinase protein (PS6K) might be associated with poor
outcome in breast cancer. In addition, the authors reported that RPS6KB1 gene
amplification and PS6K overexpression are significantly correlated. The RPS6KB1 gene
is located at 17q23 and amplified in approximately 10% of all primary breast cancer
cases. PS6K is a ribosomal protein that is involved in the progression from the G1 to S
phase of the cell cycle. It is rapidly activated in response to mitogenic stimuli, for
example, growth factors, cytokines, and oncogene products [2-15].
To study the significance of P70 S6 kinase protein compared with other established
prognostic factors in breast cancer; we have tested the prognostic significance of
PS6K overexpression in a subset of node-negative premenopausal early breast cancer
patients. In this series, we have shown previously that premenopausal node-negative
breast cancer patients whose tumours show p53 accumulation have a poor response
to one cycle of adjuvant chemotherapy, whereas patients whose tumours have no
accumulation of p53 benefit from adjuvant chemotherapy. In addition, we showed Ki-
67 overexpression, negative ER status, and young age (< 43 years) to be associated
with worse prognosis [16].
Overexpression of P70 S6 Kinase protein




All patients were drawn from EORTC trial 10854 (1986–1991, median follow up 10.8
years). This trial, which randomised 2795 patients, studied whether one course of
peri-operative chemotherapy given directly after surgery yields better results in terms
of treatment outcome than surgery alone. Peri-operative chemotherapy consisted of
one single course of doxorubicin 50 mg/m2, 5- fluorouracil 600 mg/m2, and
cyclophosphamide 600mg/m2 (FAC), administered intravenously within 36 h after
surgery. Axillary lymph node-positive premenopausal patients in the peri-operative
chemotherapy group were recommended to receive five additional cycles of
cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) postoperatively. Node-
positive patients, younger than 50 years, who did not receive peri-operative
chemotherapy, were advised to be treated with one conventional course of FAC
followed by five cycles of CMF after surgery. At randomisation, patients were stratified
for institution, age (≤ 50 years or  > 50 years) and surgical procedure (breast
conserving therapy and modified radical mastectomy). Prolonged adjuvant systemic
treatment was left to the discretion of the local investigator [17].
In total, 676 node-negative premenopausal patients were enrolled in this trial and
representative tumour material was collected for 452 patients. Tumour material
consisted of formalin fixed, paraffin-embedded tumour blocks. Tumours were
histologically typed and graded [18] centrally by one pathologist;
immunohistochemistry to assess the expression of various proteins has been
performed. Results of these studies have been reported previously [16]. For the
present study, assays were reviewed simultaneously by two investigators (M.J. van de
Vijver, J.A. van der Hage) who had to come to an agreement in case of any
uncertainties. During the evaluation of the results, the investigators were blinded for
the clinical outcome of the patients.
p70 S6 kinase protein expression
A standard indirect immunoperoxidase protocol with a 3,3’-diaminobenzidine /
imidazole solution as a chromogen was used. Before incubation with the primary
antibody, antigen retrieval was done by boiling the sections in 10mM citrate buffer for
10 min using a microwave oven. PS6K expression was determined using a polyclonal
anti-p70 s6k antibody (sc-230 Santa Cruz Biotechnology, Santa Cruz, USA) (1 : 1000
dilution in PBS containing 1% bovine serum albumin). PS6K staining was evaluated in
tumour cells and in normal ductal epithelial cells. PS6K staining was scored
categorical as: 0 = no staining; 1= weak cytoplasmic staining; 2 = moderate
cytoplasmic staining; 3 = strong cytoplasmic staining. In all cases analysed, the
staining was homogeneously distributed in the normal cells and also in the tumour
cells. If the difference in staining score between the tumour cells and the normal
epithelial ducts was greater or equal than two, tumours were deemed PS6K positive.
RPS6KB1 gene amplification
Two-colour FISH of tumor interphase nuclei was performed according to the ERBB2
short protocol of Ventana Medical Systems, Inc. (Tucson, AZ, USA). The Spectrum
Orange-labelled chromosome 17 centromeric probe was purchased from Vysis, Inc.
Overexpression of P70 S6 Kinase protein
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(Downers Grove, IL, USA), the unlabelled
bacterial artificial chromosome (BAC)
clones for PS6K was isolated from a BAC
library (RPCI-13 BAC library, Research
Genetics, Inc.). Fluorescent signals were
counted in 2 20 non-overlapping nuclei
per component. Mapping of the PS6K BAC
was verified by FISH on metaphase
chromosomes.
Other tumour markers
Previously, tumour sections had been
stained and analysed for oestrogen and
progesterone receptor status, Ki-67
positivity, P53 expression, HER2
expression, and mitotic index [16].
Statistical methods
This analysis was based on locoregional
control, distant-disease free survival, and
overall survival. Locoregional recurrence
was defined as the time to locoregional
recurrence as a first event. Locoregional
recurrences occurring simultaneously or
after the diagnosis of distant metastasis
or contralateral breast cancer or a
secondary primary tumour were
censored. Distant disease-free survival
was defined as the time to distant
metastasis or death, whichever of the
events happened first. All variables were
first analysed for their prognostic importance in a univariate analysis.
Eight potential prognostic variables were considered: PS6K (negative versus positive),
ER status (negative versus positive), PgR status (negative versus positive), HER2
overexpression (negative versus positive), Ki67 (negative, i.e. ≤ 20% of positive tumour
cells, versus positive, > 20% positive tumour cells), histologic tumour grade (grade I
versus grade II versus grade III), tumour diameter (T ≤ 2cm versus T>2cm), and p53
(negative versus positive).
To test the independent prognostic significance of PS6K overexpression, we included
PS6K together with the previously tested markers into a multivariate Cox regression
analysis for overall survival, progression-free survival, distant disease-free survival,
and locoregional control. Only markers that were significant predictors in the
univariate analysis were included in the multivariate analysis. A Cox proportional
hazards model was used for the univariate and multivariate analyses [19]. For factors
with only two levels the second one was compared to the first one, while for factors
with more than two levels dummy variables were used to compare each level to the
first one. Patients who had missing information for any of the variables in the
Overexpression of P70 S6 Kinase protein
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analysis were excluded when this variable was included in the model. All tests were
two-sided with a 5% alpha level.
Results
Patient characteristics are listed in Table 1. At the time of the analysis, the median
follow-up period was 10.8 years, 80 (18%) of the 452 patients had died, 126 (29%)
patients had experienced distant metastases or death, and 67 (15%) patients
experienced a locoregional recurrence as first event (see Table 2).
PS6K expression levels could be assessed in 430 tumours. In all, 39 tumours (9%)
showed PS6K overexpression (Table 1). Examples of PS6K overexpression are shown in
Figure 1A & B.
Univariate analyses
In the univariate analyses, we could not confirm a significant association between PS6K
overexpression and overall survival (Table 3). However, PS6K overexpression was a
significant predictor for increased risk of locoregional recurrence (HR 2.50, 95% CI
1.30–4.81, P = 0.006) and of developing distant metastases (HR 1.80, 95% CI 1.08–3.01,
P = 0.025).
Multivariate analyses
Apart from PS6K, p53 was the only significant risk factor for locoregional recurrence
in the univariate analysis. When including these two factors in a multivariate model,
PS6K appears as the only independent prognostic factor for locoregional control
predicting a poor control rate in PS6K overexpressing cases (HR 2.67, 95% CI 1.39–5.14,
P = 0.003, Table 4). Variables significantly associated with distant disease-free survival
in the univariate analysis were PS6K, ER status, Ki67, grade, and tumour diameter. In a
multivariate model including all these factors, Ki-67 overexpression was the only
independent prognostic factor associated with poor distant disease-free survival (HR
1.79, 95% CI 1.11–2.91, P = 0.018, Table 4). PS6K as a prognostic factor did not remain
significant in the multivariate analysis.
In addition, Ki-67 overexpression was an independent significant predictor for poor
overall survival.
Overexpression of P70 S6 Kinase protein
Figure 1. (A & B) Two cases of PS6K overexpressing breast cancer tumours
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PS6K overexpression in patients who underwent breast-conserving treatment
In all, 368 patients underwent breast-conserving therapy. Event rates are shown in
Table 5. The prognostic impact of PS6K was similar to that of the overall population.
PS6K remained a predictor of poor locoregional control (HR 2.83, 95% CI 1.42–5.62,
P = 0.003) but not for overall survival (HR1.44, 95 CI 0.66–3.18, P = 0.36) (Table 6). In the
multivariate analyses, Ki67 remained an independent predictor for distant disease 
(RR 1.78, 95% CI 1.03–3.07, P = 0.038). Tumour grade remained an independent
prognostic factor for poor survival (RR 1.63, 95% CI 1.04–2.53, P = 0.032) (Table 7).
FISH
A tissue microarray (TMA) was constructed from 12 tumours that showed PS6K
overexpression, as assessed by immunohistochemistry. Amplification was studied
using FISH by hybridising the TMA to a PS6K BAC probe and a CEP17 chromosome 
17 centromeric probe. Probe signals and CEP17 signals were counted in each nucleus
Overexpression of P70 S6 Kinase protein
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and a ratio of mean probe signal to mean
CEP17 signal was calculated. Ratios of X2
were scored as amplification. Eight of the
12 tumours with PS6K overexpression
(75%) showed PS6K gene amplification,
which is in accordance with the data
shown by Barlund et al [1].
Correlation between HER2 and PS6K
As the PS6K gene and the HER2 gene are
both located on chromosome 17, and
amplification has been reported to occur
in both genes simultaneously, we studied
the correlation of PS6K expression and
HER2 expression and between PS6K
expression and Ki67 expression,
respectively. Based on available data, we found a significant association between PS6K
and HER2 expression (Fisher’s exact test (two sided) P = 0.01), whereas no significant
association was found between PS6K positivity and Ki67 positivity (Fisher’s exact test
(two sided) P = 0.24).
Discussion
We have found that P70 S6 kinase protein overexpression in breast cancer is
associated with increased risk of locoregional recurrence. To our knowledge, no other
oncogenic markers as predictors of locoregional recurrence have been identified
previously. At present, the common risk factors for local control after breast-
conserving treatment are: patient age, margin status, and the presence of an
extensive intraductal component [20-23].
The addition of new predictive markers for locoregional recurrence may help in
guiding the optimal type of local therapy. This is of particular importance since local
therapy does not only have an impact on locoregional control but also on survival [24,
25]. P70 S6 kinase protein overexpression was associated with an increased risk of
locoregional recurrence when all patients were analysed. The majority of the patients
Overexpression of P70 S6 Kinase protein
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(N = 368) underwent breast-conserving
treatment. When these patients were
analysed separately, PS6K remained an
independent predictor of locoregional
recurrence. In the univariate analysis, p53
overexpression was also associated with
an increased risk of locoregional
recurrence (HR 1.85, P1= 0.027); however,
this was not the case for the subset of
patients who underwent breast-
conserving therapy (data not shown). In
addition, 5-year follow-up results
concerning the impact of P53 and PS6K
status on locoregional control demonstrate similar results.
Locoregional control rates at 5 years of follow-up are 93% (95% CI 92.3–94.2) in P53
negative vs. 84% (95% CI 81.7–87.2) in P53-positive patients and 93% (95% CI 91.8–93.7)
vs 83.3% (95% CI 79.0–87.5), respectively.
Several studies have examined the relation between P53 overexpression and local
breast tumour recurrence. A case–control study of 66 women with local breast tumour
relapse following lumpectomy and radiation therapy showed that p53 overexpression
was an independent predictive factor for ipsilateral breast tumour recurrence (IBTR)
[26]. Recent studies conducted by Turner et al [26] and Zellars et al [27] demonstrated
predictive significance of P53 overexpression for locoregional recurrence in patients
who underwent breast-conserving therapy, as well as in patients who underwent
mastectomy. Turner and colleagues showed in a matched case-control study
comprising 47 cases and 47 controls that overexpression of P53 had prognostic
significance in respect to IBTR following lumpectomy and radiotherapy (P = 0.003).
Zellars and co-workers demonstrated in 1530 mastectomy-treated breast cancer
patients of whom 259 received adjuvant radiotherapy that P53 overexpression was
independently associated with a significantly increased local failure rate in patients
treated with mastectomy, with (RR 2.5, 95% CI 1.1–5.7) or without (RR 1.7, 95% CI
1.2–2.4) radiotherapy. Although, in our series, P53 lost its prognostic significance in
the multivariate analysis, a trend still remained, suggesting worse locoregional
recurrence rates in P53-overexpressing tumours (RR 1.67, 95% CI 0.95–2.96).
Barlund et al [1] analysed RPS6KB1 amplification using FISH in 668 informative
primary breast tumours. In all, 9% of the tumours showed amplification of the
RPS6KB1 gene. In their series, PS6K was significantly associated with poor survival (P
= 0.0021). In addition, the authors analysed overexpression in a subset of 445 primary
breast tumours. P70 S6 kinase protein staining of cytoplasm was subjectively scored
into four groups: negative (no staining), weak, moderate, or strong staining. For
statistical analyses, the data were combined into two groups: low expression (nega-
tive or weak staining) and high expression (moderate or strong staining). High expres-
sion was seen in 15.6%. There was a statistically significant association between
RPS6KB1 amplification and high P70 S6 kinase protein expression (P = 0.0004), with
41% of the amplified tumours (FISH) exhibiting high PS6K expression, and over-
expression of PS6K was associated with poor survival (P = 0.0083) as well. Our results
suggest an even stronger association between amplification and expression, albeit
Overexpression of P70 S6 Kinase protein
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with not enough data to make a sound statistical comparison. Moreover, the authors
found that patients showing both PS6K and HER2 amplification had a significant
worse prognosis in terms of breast cancer-specific survival than those with no
amplification or amplification of only one of the genes. These results together with
our data suggest that P70 S6 kinase protein overexpression may be an important
predictor of not only worse survival but also of poor locoregional control.
Overexpression of P70 S6 Kinase protein
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CHAPTER 6
Impact of locoregional treatment on 
the early-stage breast cancer patients: 
a retrospective analysis
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Abstract
Although adequate locoregional treatment improves local and regional control in early-stage
breast cancer, uncertainty still exists about the role of locoregional therapy with respect to
survival.
To study the impact of surgery and radiotherapy on locoregional control and survival, we
combined the data of three European Organisation for Research and Treatment of Cancer (EORTC)
Breast Cancer Group trials including early-stage breast cancer patients with long-term follow-up.
Risk ratios (RR) were estimated for locoregional recurrence and overall survival using Cox
regression models. All analyses were adjusted for tumor size, nodal status, age, adjuvant
radiotherapy, adjuvant chemotherapy and trial.
The combined data set consisted of 3648 patients. The median follow-up period was 11 years. 5.9%
of the patients who underwent mastectomy and 10.8% of the patients who underwent breast-
conserving therapy had a locoregional recurrence (P < 0.0001). The risk of death after breast-
conserving therapy was similar compared with mastectomy (RR 1.07, P = 0.37). Adjuvant
radiotherapy after mastectomy was associated with a lower risk for locoregional recurrence (RR
0.43, P < 0.001) and death (RR 0.73, P = 0.001). Patients with 1–3 positive nodes benefited the most
from radiotherapy after mastectomy. Breast-conserving therapy was associated with an impaired
locoregional control. However, breast- conserving therapy was not associated with a worse overall
survival. Adjuvant radiotherapy in mastectomised patients was associated with both a
significantly superior locoregional control and overall survival.The effect of adjuvant radiotherapy
was most profound in patients who had 1–3 positive nodes.
Introduction
It has long been accepted that adequate locoregional therapy can delay or prevent
local or regional recurrence in women with early breast cancer. In addition, the
detrimental impact of locoregional recurrence on disease outcome has been firmly
established [1,2].
Many investigators have studied the role of locoregional control and its impact on
disease outcome. The predominating assumption is that locoregional recurrence is an
independent prognostic factor that is associated with a poor outcome. However, more
aggressive locoregional treatment has not been reported to result in better survival
despite improved locoregional control.
Therefore, locoregional recurrence is not regarded as an instigator of subsequent
systemic disease. Locoregional therapy is based on surgery and radiation therapy.
Trials that studied breast-conserving surgery versus mastectomy have failed to detect
a difference in overall survival, despite demonstrating a superior locoregional control
after mastectomy [1,3–5]. However, randomised trials that studied the role of adjuvant
radiotherapy after mastectomy in patient samples that were at a high risk of
recurrence demonstrated superior locoregional control as well as superior overall
survival rates after adjuvant radiotherapy [6,10–13]. The fact that radiotherapy may
influence disease outcome, but more aggressive surgery may not, is intriguing. The
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most recent follow-up of the Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG 2000 update) demonstrated a significant overall survival difference of 6.0%
in favour with patients who underwent mastectomy compared to patients who
underwent breast-conserving surgery without radiotherapy at 15 years of follow-up
(survival rates of 53 and 47%, respectively).
This effect was observed in 2489 randomised patients. However, in 4463 women
randomised between mastectomy and conservative surgery plus radiotherapy, the
survival patterns were very similar after 15 years of follow-up (overall survival of 61
and 60.8%, respectively; EBCTCG 2000 update).
Adjuvant radiotherapy trials have demonstrated a beneficial effect for radiotherapy
on overall survival after mastectomy in high-risk early breast cancer patients.
However, data from the 2000 update of the EBCTCG concerning the effects of
radiotherapy on overall survival are still inconclusive, in that the beneficial effect of
radiotherapy on breast cancer mortality is balanced by its negative impact on cardiac
mortality [6].
We hypothesised that any improvement in survival through locoregional therapy has
to be accompanied by an improvement in local control. The rationale behind this is, of
course, that locoregional therapy is directed against locoregional disease and not
against systemic micrometastases. The combination of data from different trials
provides a larger sample size, which increases the possibility of finding small, but
clinically relevant, differences between locoregional treatment modalities. Therefore,
we conducted a retrospective analysis combining the data of three trials with
sufficient follow-up, which enrolled early breast cancer patients who either underwent
mastectomy or breast-conserving therapy, to study whether more aggressive surgery
would result in better overall survival rates in a large set of early breast cancer
patients. It was decided to select patients with T1 and T2 tumors since these patients
can generally be treated by either mastectomy or breast-conserving surgery.
Patients and methods
Selection of the trials
Patients were selected from trials that randomized early-stage breast cancer patients.
The European Organisation for Research and Treatment (EORTC) has conducted
several large randomised phase III trials concerning the management of breast cancer
patients with stage I or stage II/III breast cancers. These trials, EORTC trial 10801,
10854, and 10902 have enrolled a total of over 4018 early breast cancer patients.
Median follow-up periods ranged from 6.1 to 13.4 years in these studies. From these
trials, all patients who had clinical T1 or T2 tumors at the time of diagnosis were
selected. Patient characteristics are listed in Table 1. A brief description of these trials
follows below:
EORTC trial 10801 (1980–1986, median follow-up of 13.4 years) was conducted in order
to assess the safety of breast-conserving treatment. In this trial, patients were
randomised between breast-conserving surgery combined with radiotherapy and
radical mastectomy. Six cycles of adjuvant chemotherapy with cyclophosphamide 
100 mg/m2 given orally on days 1–14, methotrexate 40 mg/m2 given intravenously (i.v.)
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on days 1 and 8, and 5-fluorouracil (5-FU) 600 mg/m2 given i.v. on days 1 and 8, were
indicated for all patients under the age of 55 years with positive nodes. No
information was collected on hormonal therapy. In this study, 902 patients were
randomised [3].
EORTC trial 10854 (1986–1991, median follow-up of 10.8 years) studied the question
whether one course of perioperative chemotherapy given directly after surgery yields
better results in terms of treatment outcome than surgery alone. Perioperative
chemotherapy consisted of one single course of doxorubicin 50 mg/m2,
5-FU 600 mg/m2 and cyclophosphamide 600 mg/m2 (FAC), administered i.v. within 
36 h after surgery. Axillary lymph node-positive premenopausal patients in the
perioperative chemotherapy group were recommended to receive an extra five cycles
of cyclophosphamide, methotrexate and 5-FU (CMF). Node-positive patients, younger
than 50 years, who did not receive perioperative chemotherapy, were advised to
receive one conventional course of FAC followed by five cycles of CMF after surgery.
Patients were stratified for breast-conserving therapy and modified radical
mastectomy. Prolonged adjuvant systemic treatment was left to the discretion of the
local investigators. 2795 patients were included in this trial [7].
EORTC trial 10902 (1991–1999, median follow-up of 6.1 years) was set up to determine
the value of preoperative chemotherapy. Patients were randomised to receive four
cycles of chemotherapy either before or after surgery. Chemotherapy consisted of four
cycles of 5-FU 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2
(FEC) administered i.v., at 3-weekly intervals. In the preoperative chemotherapy group,
surgical therapy followed within 4 weeks of the fourth course of chemotherapy. In the
postoperative chemotherapy group, the first cycle was given within 36 h after surgery.
Stratification was performed for planned type of surgery instead of performed type of
surgery. This was done because of the expected effect of preoperative chemotherapy
on downstaging of the tumor. A total number of 698 patients were randomised [8].
Selection of data
All of eligible patients from all the trials were included in the analysis, with the
exception of patients who underwent preoperative chemotherapy in EORTC trial
10902. These patients would have introduced a selection bias since preoperative
chemotherapy influences the choice of locoregional treatment due to tumor
downstaging.
Selection of covariates
To study the independent impact of surgery and radiotherapy on locoregional control
and overall survival, we included the following covariates; clinical tumor size,
pathological nodal status, age, type of surgery, adjuvant radiotherapy, adjuvant
chemotherapy, and the trial in which a patient participated. Clinical tumor size was
measured taking the largest diameter using callipers. Pathological tumor size,
hormone receptor status and tamoxifen use were not taken into account as these
tumor- and treatment-related characteristics were poorly reported in some of the
trials. Specifications on the radiotherapeutic regimens used differed between the
trials and the institutions in which patients were treated. Therefore, it was decided
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that any type of radiotherapy given to a patient after surgery should be regarded as
adjuvant radiotherapy without specification of radiation fields and doses.
Locoregional treatment
In all of the trials, patients were selected for breast-conserving therapy if a wide local
excision could be performed provided that at least a 1-cm margin around the
macroscopic dimension of the tumor could be achieved. Patients who received breast-
conserving therapy underwent lumpectomy plus axillary lymph node dissection and
radiotherapy to the whole breast, with or without a boost. Radiotherapy to the axilla
was given in cases of extensive lymph node metastasation (pN1-bii/ pN2) or in cases
of positive nodes in level III of the axilla. All patients who underwent mastectomy
underwent axillary lymph node dissection. Postoperative radiotherapy to the breast
was always indicated after breast-conserving surgery. In EORTC trials 10854 and
10902, postoperative radiotherapy to the chest wall and parasternal lymph node chain
after mastectomy was indicated if surgery was considered not to be radical, if the
tumor was >5 cm, or if a positive infraclavicular node was found after surgery. In
EORTC trial 10801, microscopically-incomplete excision was not a reason for
exclusion. Lumpectomy was followed by radiotherapy (50 Gy over a 5-week period),
with an additional booster dose of 25 Gy directed to the lumpectomy site via an
Iridium-192 implant. If implants could not be used for technical reasons, patients
were given an equivalent booster dose with external irradiation. Postoperative
irradiation to the chest wall was indicated after a  microscopicallyincomplete
operation. General guidelines concerning adjuvant radiotherapy were as follows: for
patients both after mastectomy or breast-conserving therapy, irradiation of the
parasternal lymph node region was indicated for patients with a centrally or medially
localised tumor and for patients with a lateral tumor and histologically-proven
axillary lymph node metastases. Postoperative radiation was always given in cases in
which surgery was considered not to be radical. In cases of breast-conserving surgery,
microscopically incomplete or not, the whole breast was irradiated using a dose of at
least 50 Gy followed by a boost on the initial tumor of at least 16 Gy.
Statistical methods
To compare different locoregional treatment modalities, type of surgery was divided
into two states; breast-conserving therapy (lumpectomy plus axillary lymph node
dissection followed by radiotherapy) and (modified) radical mastectomy, with or
without radiotherapy. All analyses were performed for overall survival and
locoregional recurrence. Survival time was defined as the time between randomisation
and death from any cause. A locoregional recurrence was defined as any recurrence in
the breast or axilla. Only recurrences, which occurred before the diagnosis of a distant
metastasis and/or a new primary tumor, were regarded as a locoregional recurrence as
the first event included in the analysis. In EORTC trial 10854, any chemotherapy (1x
perioperative FAC) was scored as having received chemotherapy. Cox proportional-
hazard regression models [9] were used to estimate the hazard ratios with their 99%
confidence intervals (CIs). Since the number of patients is high, a 1% significance level
was used. All tests are two-sided. To control for possible differences in the study
populations, we added study as a factor in the multivariate Cox regression analysis,
after testing the proportional hazards assumption.
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In total, 4018 primary operable breast
cancer patients were randomised to one
of the trials. Of these patients, 3886
breast cancer patients were deemed
eligible. 3648 patients had cT1 or cT2
tumors and were subsequently included
in the analysis. At the time of the
analysis, the median follow-up period in
this subset of patients was 11 years, 1091
patients have died, and 314 patients have
developed a locoregional recurrence as
their first event. Other patient
characteristics are listed in Table 1. 2011
patients (55%) underwent breast-
conserving therapy. Breast-conserving therapy consisted of lumpectomy and axillary
lymph node dissection followed by adjuvant radiation therapy. 1633 patients
underwent a (modified) radical mastectomy. In total, 804 (49%) patients received
adjuvant radiotherapy to the chest wall and/or the axilla after mastectomy (Table 2).
Overall analysis
Overall, 5.9% of the patients who underwent mastectomy and 10.8% of the patients
who underwent breast-conserving therapy experienced a locoregional recurrence (as
the first event) (Chi square test P < 0.0001). Overall survival rates were slightly better
for patients who underwent breast-conserving therapy, 72.3% versus 67.5%,
respectively.
In the multivariate analysis, breast-conserving therapy was significantly associated
with a poor locoregional control (Risk Ratio (RR) 2.25, P < 0.001, Table 3). Age <50 years
at the time of diagnosis was an independent predictor of a poor locoregional control
(Table 3). Additional covariates associated with an improved locoregional control were
adjuvant radiotherapy and chemotherapy. Although breast-conserving therapy was
associated with a poor locoregional control, there was no association with poor
outcome in terms of overall survival (BCT: RR 1.07, P = 0.37). Significant independent
predictors of a poor overall survival were involved axillary nodes, tumor size >2 cm
and age >50 years at the time of diagnosis (Table 3). Again, adjuvant radiotherapy and
chemotherapy were associated with an improved overall survival. In addition, in 452
patients aged <40 years at the time of diagnosis, breast-conserving therapy was not
associated with an impaired locoregional control or overall survival. The RRs for
locoregional recurrence and overall
mortality after breast-conserving therapy
were 1.31 (99% CI 0.49–3.56, P = 0.48) and
0.76 (99%CI 0.45–1.29, P = 0.18),
respectively (Table 4). To study the effect
of (prolonged) adjuvant chemotherapy
alone, we repeated the analysis excluding
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Table 2. Patients who underwent mastectomy
to the chest wall and/or axilla
Table 1. Patient characteristics (N=3648) 
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patients who received perioperative chemotherapy. Breast-conserving therapy
remained the strongest predictive factor for locoregional recurrence (RR 2.31, P <
0.001). In addition, young age remained a significant predictor of poor locoregional
control and the effect of adjuvant radiotherapy on locoregional control remained
unchanged (data not shown). In the overall survival multivariate analysis, nothing
changed except for the fact that age lost its prognostic significance (data not shown).
Mastectomy with or without radiotherapy
Forty-nine percent of patients who underwent mastectomy subsequently received
radiotherapy. Adjuvant radiotherapy after mastectomy decreased locoregional
recurrence rates independent of the TNM stage, patient’s age, and whether they
received adjuvant chemotherapy (RR 0.43, P < 0.001) (Table 5). Furthermore, it was the
only independent predictor of a better locoregional control among these covariates.
In addition, patients who received radiotherapy had a lower risk of dying (RR 0.73,
P = 0.001) compared with patients who did not receive adjuvant radiotherapy 
(Table 5).
Adjuvant chemotherapy was also independently associated with a better outcome in
terms of decreased mortality (RR 0.77, P = 0.01). Independent predictors for a poor
overall survival were a positive nodal status and tumor size >2 cm.
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Table 4. Multivariate Cox regression analysis patients younger than or equal to 40 years 
(N = 452)
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Subgroup analyses were undertaken in order to study whether the effect of adjuvant
radiotherapy after mastectomy could be demonstrated in node-positive, as well as
node-negative, breast cancer patients. Node-positive patients benefited in terms of an
improved locoregional control (RR 0.36, 99% CI 0.17–0.77, P = 0.001). However, in node-
negative patients, radiotherapy was not associated with a better locoregional control
(RR 0.56, 99% CI 0.22–1.45, P = 0.12). In terms of overall survival, node-positive patients
who received radiotherapy had better overall survival rates than patients who did not
(RR 0.70, 99% CI 0.52–0.94, P = 0.002). This could not be shown in the node-negative
patient group in which no advantageous effect of adjuvant radiotherapy could be
demonstrated (RR 0.87, 99% CI 0.56–1.34, P = 0.40). In patients who underwent
mastectomy and had 1–3 positive nodes, radiotherapy was associated with
significantly improved survival rates (RR 0.48, 99% CI 0.31–0.75, P = <0.001, Table 6a).
However, in patients with four or more positive nodes, no significant association
between radiotherapy and overall survival was found (Table 6b).
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Table 6.
A. Multivariate Cox regression analysis mastectomized patients with 1-3 positive nodes 
(N = 507)
B. Multivariate Cox regression analysis mastectomized patients with 4+ positive nodes 
(N = 381)
Table 5. Multivariate Cox regression analysis mastectomized patients (N = 1633)
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Discussion
The central question regarding locoregional therapy (i.e. surgery and radiotherapy) for
early breast cancer remains; that is, whether more aggressive locoregional treatment
significantly reduces long-term mortality from breast cancer. For example, the EORTC
trial 10801 [3], which randomised between modified radical mastectomy and breast-
conserving surgery demonstrated a significant difference in terms of local control in
favour of the modified radical mastectomy arm after a long-term follow-up. The
respective local control rates were 87% after radical mastectomy and 77% after breast-
conserving therapy at 13 years of follow-up. However, overall survival was not
significantly different between the arms. To study both treatment modalities in a
large non-randomised sample, we combined the data of three controlled clinical trials
conducted by the EORTC Breast Cancer Group studying different treatment regimens
in early breast cancer patients. As mentioned before, the analyses in this study are
based upon non-randomised comparisons. In our series, the most important
predictor of locoregional recurrence was undergoing breast-conserving surgery. This is
a striking finding considering the fact that breast-conserving therapy is well
established in the management of early-stage breast cancer. The underlying cause for
this effect may be due to inadequate surgical margins, which are known to impair
local control after breast-conserving surgery [14–16]. Unfortunately, we were not able
to retrieve this information from the case report forms, so a definite answer to this
question cannot be given. However, the increased risk for locoregional recurrence
after breast-conserving therapy did not result in an increased risk for worse overall
survival. This is in accordance with the results of the randomised trials comparing
breast-conserving surgery and mastectomy [3-5], as well as with the meta-analyses
conducted by the EBCTCG. This underlines the fact that the majority of early
locoregional recurrences after breast-conserving therapy are associated with a poor
prognosis, but are not instigators of the subsequent systemic spread [1,17]. In
addition, late recurrences and second ipsilateral primary tumors can be treated well
with salvage mastectomy and have a much less detrimental effect on prognosis
compared with early recurrences. Although the median follow-up of this analysis was
11 years, this period may be to short to detect a survival benefit if the impact of more
aggressive surgery on survival occurs after a longer follow-up, i.e. 15–20 years.
Therefore, it must be stressed that the impact of surgery on outcome in breast cancer
has to be followed-up in the future. Breast cancer at a young age, i.e. younger than
35/40 years at the time of diagnosis, is often associated with a poor prognosis [18–21].
In addition, young breast cancer patients have been reported to be at a higher risk of
local recurrence, especially after breast-conserving therapy [22,23]. In line with these
data, our results also demonstrate that young age, i.e. lower than 50 years, is
associated with a poor locoregional control. Remarkably, in our analysis, breast-
conserving therapy was not associated with a higher risk for locoregional recurrence
or death in women younger than or equal to 40 years. Patients that underwent
mastectomy and subsequently received adjuvant radiotherapy were at a lower risk for
locoregional recurrence in our analysis and this resulted in a lower risk of death as
well. Two randomized trials in high-risk breast cancer patients conducted by the
Danish Breast Cancer Study Group and one Canadian trial have previously
demonstrated a survival benefit for adjuvant radiotherapy after mastectomy [10–12].
Impact of locoregional treatment on the early-stage breast cancer patients
06 Prfschrft JvdH Binnenwerk  23-04-2006  16:07  Pagina 91
92
However, the quality of surgery in these trials was very poor, especially the
management of the axilla, resulting in recurrence rates exceeding 20% after 10 years.
Therefore, radiotherapy may have compensated for inadequate surgery in these trials.
In addition, results from a meta-analysis performed by the EBCTCG demonstrated a
trade-off effect due to an increase in cardiac-related  mortality after adjuvant
radiotherapy, which equalled the decrease in breast cancer-related mortality induced
by radiotherapy [6]. It has been proposed that the detrimental effects of radiotherapy
are mainly attributable to older trials (conducted before 1975) that used obsolete
radiotherapy regimens causing excessive damage to the heart (EBCTCG 2000 update).
In our analysis, patients were included who had participated in trials conducted
between 1980 and 1999. The median follow-up was 11 years at the time of the diagnosis
and our results show a definite favourable effect for radiotherapy after mastectomy in
terms of overall survival. This suggests that, in this series, in which the radio-
therapeutic regimen that was given to patients varied widely, adjuvant radiotherapy
directed at either the chest wall or the axilla resulted in an absolute gain in survival.
However, adjuvant radiotherapy only contributed to locoregional control and overall
survival in node-positive patients. In the node-positive group, an association between
radiotherapy and a favourable outcome was seen, especially in patients with 1–3
positive nodes as opposed to patients with four or more positive lymph nodes. This
remarkable finding is in accordance with the results from the Danish radiotherapy
trials [7,8] in which patients with limited nodal involvement benefited more from
adjuvant radiotherapy than patients with extensive nodal disease. A possible
explanation for this difference is that node-positive patients benefit from radiotherapy
due to the local eradication of residual tumor cells. In patients with four or more
positive lymph nodes, systemic spread of tumor cells may be much more extensive
compared with patients with 1–3 positive nodes and therefore locoregional therapy will
not have a significant impact on survival in these patients.
This stresses the need for trials studying the management of the axilla. The EORTC
Breast Cancer Group is currently conducting a trial in which sentinel node-positive
patients are randomised between axillary lymph node dissection and radiotherapy
[24].
Many investigators have tried to divide locoregional recurrences into a category that
are merely associated with distant disease and a category that are the instigators of
distant disease [25–35]. Although these were retrospective analyses, a short disease-
free interval between primary therapy and adverse primary tumor characteristics
have been identified as predictors for poor outcome after locoregional recurrence. In
addition, a small locoregional recurrence (<1 cm) was associated with a favourable
prognosis, suggesting an advantageous effect for early detection [31]. Finally, it must
be emphasised that this is was a non-randomised, retrospective analysis and,
therefore, our results should be interpreted with caution and be considered
hypotheses rather than conclusions. Nevertheless, the apparent lack of benefit of
mastectomy in young patients, in terms of locoregional control, and the lack of
benefit in the general population, in terms of overall survival, once again raises the
question of whether breast cancer patients should receive more aggressive surgery. In
addition, the differences in the efficacy of radiotherapy between patients with only a
few involved nodes (1–3) and those with more involved nodes (54) have to be
evaluated more thoroughly. However, any recurrence, either an associative factor or
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an instigator of distant spread, is an emotionally devastating event for the patient
[36]. Therefore, any treatment strategy against breast cancer should include an
adequate local therapy in order to avoid unnecessary locoregional recurrences. The
fact that an adequate local therapy may improve survival provides further support for
this argument.
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CHAPTER 7
Isolated loco-regional recurrence of breast
cancer is more common in young patients and
following breast conserving therapy: Long-term
results of European Organization for Research
and Treatment of Cancer studies
G.H. DE BOCK, J.A. VAN DER HAGE, H. PUTTER, J. BONNEMA, H. BARTELINK, C.J.H. VAN DE VELDE
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Abstract
The aim of this study was to evaluate prognostic factors for isolated loco-regional recurrence in
patients treated for invasive stage I or II breast cancer. The study population comprised 3602
women who had undergone primary surgery for early stage breast cancer, who were enrolled in
European Organisation for Research and Treatment of Cancer (EORTC) trials 10801, 10854, or 10902,
by breast conservation (55%) and mastectomy (45%). The median follow-up time varied from 5.3
(range: 0.6–9.5) to 11.9 years (range: 0.6–17.4). Main outcome was the occurrence of isolated loco-
regional recurrence. The results of multivariate analysis showed that younger age and breast
conservation were risk factors for isolated loco-regional recurrence (breast cancer under 35 years
of age versus over 50 years of age: hazard ratio 2.80 (95% CI 1.41–5.60)); breast cancer age 35–50
years versus over 50 years: hazard ratio 1.72 (95% CI 1.17–2.54); breast conservation (hazard ratio:
1.82 (95% CI 1.17–2.86)). After perioperative chemotherapy, less isolated loco-regional recurrences
were observed (hazard ratio 0.63 (95% CI 0.44–0.91)). No significant interaction effects were
observed. It is concluded that young age and breast conserving therapy are both independent
predictors for isolated loco-regional recurrence. As an isolated loco-regional recurrence is a
potentially curable condition, women treated with breast conservation or diagnosed with breast
cancer at a young age should be monitored closely to detect local recurrence at an early stage.
Introduction
Loco-regional recurrence of breast cancer is of concern in breast cancer treatment, as
it is a well-established independent risk factor for distant metastases and death [1,2].
Many studies have looked for factors associated with the increased risk of loco-
regional recurrence [3]. A well-known risk factor is breast conserving surgery, being
associated with a higher risk of loco-regional recurrence, compared with mastectomy
[4–8].
Risk factors for local recurrence frequently reported in patients treated with breast
conserving therapy are: positive margin status, extensive intraductal component and
young age of diagnosis of primary tumour [3, 9–12]. Risk factors commonly reported
for loco-regional recurrence in patients treated primarily with mastectomy are
histological grade, and extensive axillary node involvement [13,14]. We studied risk
factors at primary diagnosis of early breast cancer associated with isolated loco-
regional recurrence and other recurrences, including distant metastases or death
irrespective of primary treatment. We focused on isolated loco-regional recurrences,
because these recurrences are not associated with distant metastases and are, in
principle, curable, To do this, we re-analysed the data of 3602 patients with early stage
breast cancer surgically treated and recruited in three European Organization for
Research and Treatment of Cancer (EORTC) trials (studies 10801, 10854 and 10902).
Within all three studies, patients were treated with mastectomy or with breast
conserving therapy, which allowed us to study prognostic factors in relation to
primary treatment.
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Patients and methods
Selection of trials and patients
Patients were selected from trials that randomised early stage breast cancer patients.
EORTC has conducted several large randomised phase III trials concerning the
optimal management of breast cancer in patients with stage I or II breast cancer.
A total of 4395 breast cancer patients have been enrolled for these trials; EORTC trials
10801, 10854 and 10902. Patients treated with pre-operative chemotherapy (n = 377),
those not eligible for the study (due to false inclusion or severe protocol violation,
n = 88), those with stage III breast cancer (n = 238) and those without full information
on all co-variates (n = 90) were excluded from the analysis. A summary of the 3602
included patients is given in Table 1. For a short summary of the outcomes, the
median overall follow-up times, and the median follow-up times to first event, see
Table 2. A brief description of these trials follows.
EORTC trial 10801 (1980–1986)was conducted in order to assess the safety of breast
conserving treatment. In this trial, patients were randomised between breast
conserving surgery combined with radiotherapy, and modified radical mastectomy.
Six cycles of adjuvant chemotherapy with cyclophosphamide (100 mg/m2) given orally
on days 1–14, methotrexate (40 mg/m2) given intravenously on days 1 and 8, and 
5-fluorouracil (600 mg/m2) given intravenously on days 1 and 8, were indicated for all
Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy
Table 1: Characteristics of the patients (3,602) included in this analysis per study and 
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patients under the age of 55 years with positive nodes. No information was collected
on hormonal therapy. In this study, 902 patients were randomised [5,15,16].
EORTC trial 10854 (1986–1991) considered the question of whether one course of
perioperative chemotherapy given directly after surgery yields better results in terms
of treatment outcome than surgery alone. Perioperative chemotherapy consisted of
one single course of doxorubicin (50 mg/m2), 5-fluorouracil (600 mg/m2) and
cyclophosphamide (600 mg/m2) (FAC), administered intravenously within 36 h after
surgery. It was recommended that axillary lymph node-positive pre-menopausal
patients in the perioperative chemotherapy group received an extra five cycles of
cyclophosphamide, methotrexate and 5-fluorouracil (CMF). The advice for node-
positive patients, younger than 50 years, who did not receive perioperative
chemotherapy, was one conventional course of FAC followed by five cycles of CMF
after surgery. Patients were stratified for breast conserving therapy and modified
radical mastectomy. Prolonged adjuvant systemic treatment was left to the discretion
of the local investigators. A total of 2795 patients were included in this trial [17–19].
EORTC trial 10902 (1991–1999) was set up to determine the value of pre-operative
chemotherapy. Patients were randomized to receive four cycles of chemotherapy
either before or after surgery. Chemotherapy consisted of four cycles of 5-fluorouracil
(600 mg/m2), epirubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (FEC)
administered intravenously, at 3-weekly intervals. In the pre-operative chemotherapy
group, surgical therapy followed within 4 weeks of the fourth course of chemotherapy.
In the postoperative chemotherapy group, the first cycle was given within 36 h after
surgery. A total of 698 patients were randomised [20].
Assessments and statistical methods
Endpoints for this study were: (i) isolated loco-regional recurrences, (ii) all other
events, including distant metastases or death. Non-isolated loco-regional recurrences
were considered as distant metastases. A loco-regional recurrence was defined as any
recurrence in the ipsilateral breast, axilla or chest wall. A loco-regional recurrence
was considered isolated if for a period of 2 years after the loco-regional recurrence
occurred, no distant metastasis or death was observed. A loco-regional recurrence
was considered non-isolated if distant metastasis was observed before, or
concomitantly with, or within a period of 2 years after the occurrence of the loco-
regional recurrence. In the database we could not discern breast cancer specific death
from other causes of death, so all causes of death were considered as one group. The
following characteristics were considered: tumour size (62 cm, 2–5 cm), axillary nodal
status positivity (no, yes), oestrogen receptor positive (yes, no), age at diagnosis (635,
36–50, >50 years), surgical therapy (mastectomy, breast conserving therapy), margins
free (yes, no), perioperative chemotherapy (yes, no), adjuvant chemotherapy (yes, no),
adjuvant radiotherapy (yes, no) and tamoxifen (yes, no) (see Table 1). The values for all
characteristics were based on clinical observations. Survival time was defined as the
time between randomisation and the occurrence of the first events (loco-regional
recurrence, distant metastasis or death from any cause) or last date of follow-up.
Multivariate Cox proportional-hazard regression models were used to estimate
hazard ratios with their 95% confidence intervals (CIs). All tests were two-sided. To
Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy
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test the assumption of proportional hazards, an interaction term of a prognostic
variable and a time-dependent covariate was added [21]. To control for unmeasured
possible differences in study populations, we added study as a factor in the
multivariate Cox regression analysis. Two years disease-free follow-up was taken as
cut-off for an isolated loco-regional recurrence because the incidence of metastases
lowers after that [22]. Because this point is not clear-cut, in a sensitivity analysis we
varied this cut-off point between 3 months, 1 year and 5 years.
Results
In all, 55% of the patients underwent breast conserving therapy (Table 1). An isolated
loco-regional recurrence without distant metastasis or death within 2 years of follow-up
was observed in 172 (4.8%) of the patients (Table 2). Another event (a distant metastasis
or death) occurred in 1182 (32.8%) of the patients. A total of 55 (32%) of the isolated loco-
regional recurrences were seen in patients treated with mastectomy, and 117 (68%) were
seen in patients treated with breast conserving therapy (data not in table).
From the multivariate Cox regression analyses (Table 3) it appeared that significant
risk factors for isolated loco-regional recurrence were: younger age at diagnosis of
breast cancer, breast conserving therapy and no perioperative chemotherapy. Risk for
isolated loco-regional recurrence for women under 35 years of age was compared
with over 50 years of age: hazard ratio 2.34 (1.30–4.24); 35–50 years: hazard ratio 1.60
(1.14–2.25). Risk for loco-regional recurrence for breast conserving therapy compared
with mastectomy: hazard ratio 1.82 (1.17–2.86). Less frequent isolated loco-regional
recurrences were observed after perioperative chemotherapy (hazard ratio 0.63
(0.44–0.91)).
In a model predicting loco-regional recurrence including age at diagnosis, surgical
therapy and an interaction effect between these two, no statistically significant
effects other than already reported, were observed (results not presented). In the
multivariate Cox regression analyses more distant metastases and deaths were
observed in very young patients (under 30 years of age, hazard ratio: 1.55 (1.20–2.00));
in patients with larger tumour size (hazard ratio 1.56 (1.35–1.80)); and in patients with
positive nodal status (hazard ratio 2.12 (1.81–2.47)). In patients treated with adjuvant
chemotherapy less distant metastases or deaths were also observed (hazard ratio 0.66
(0.54–0.79)).
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Subsequently the definition of an isolated loco-regional recurrence was varied: 
(a loco-regional recurrence was considered isolated if for a period of 3 months, 1 year
and 5 years (instead of 2 years) after the loco-regional recurrence occurred, no distant
metastasis or death was observed). It was found that a less restrictive definition 
(a shorter timeframe without any event after loco-regional recurrence was observed)
reduced the prognostic effects of age and perioperative chemotherapy; meanwhile, it
enhanced the prognostic effects of surgical therapy and adjuvant radiotherapy (see
Table 4). A more restrictive definition (a longer time-frame after loco-regional
recurrence without any event was observed) enhanced the prognostic effects of age
and perioperative chemotherapy. Due to smaller numbers of patients, the confidence
intervals are wider. With regard to distant metastasis, death, or non-isolated loco-
regional recurrences, the hazards were not influenced, mainly due to the fact that the
relative change in number was very small (results not presented).
Discussion
The major risk factor for an isolated loco-
regional recurrence in this analysis was
younger age as well as breast
conservation (breast cancer under 35
years of age: hazard ratio 2.80 (1.41–5.60));
breast cancer between 35 and 50 years of
age: hazard ratio 1.72 (1.17–2.54); breast
conservation (hazard ratio: 1.82
(1.17–2.86)). No significant interaction
effects between these two variables were
observed. After perioperative
chemotherapy, less isolated loco-regional
recurrences were observed (hazard ratio
0.63 (0.44–0.91)), which has been
published earlier [20]. Prognostic factors
for distant metastases or deaths were
larger tumour size (hazard ratio 1.56
(1.35–1.80)), positive nodal status (hazard
ratio 2.12 (1.81–2.47)), and breast cancer
under 35 years (hazard ratio 1.55
(1.20–2.00)). After adjuvant chemotherapy
less distant metastases or death were
observed (hazard ratio 0.66 (0.54–0.79)).
No significant interaction effects were
observed. Young age (breast cancer
diagnosed before 35 years) was a
predictor for isolated loco-regional
recurrence as well for other recurrences.
Young age is generally accepted as being
a prognostic factor for worse loco-
Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy
Table 3: Multivariate analyses of all patients
related to outcomes (first events) (Hazard
Ratio’s and 95% C.I.)
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regional control in breast cancer [3,9–12]. However, it has been reported that this is
not the case for radical mastectomy [14]. Although the absolute number of isolated
loco-regional recurrences was higher after breast conserving therapy than after
mastectomy in our series, the effect of young age on the occurrence of isolated loco-
regional recurrences was not different in patients treated with breast conserving
therapy or mastectomy. Arriagada and colleagues found the same negative effect of
young age as we did on loco-regional control irrespective of the type of surgery [14].
Other reported risk factors for local recurrences in patients treated with breast
conserving therapy are positive margin status and extensive intraductal component
[3,9–12]. Because these measurements were not consistently assessed in the included
studies, they could not be studied. Risk factors reported for loco-regional recurrences
in patients primarily treated with mastectomy are histological grade, and extensive
axillary node involvement (10 nodes or more) [13,14]. We could not confirm these
findings in our study, which might be explained by the more restricted definition of
loco-regional recurrences we used (i.e., not followed by distant metastases within 
2 years of follow-up). The impact of loco-regional recurrences on overall survival has
not been demonstrated in trials which randomised between breast conserving
therapy and mastectomy [13,23,24]. This means that some loco-regional recurrences
are potentially curable, as they are not followed by further distant spread of the
Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy
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disease. Whether adjuvant chemotherapy is effective in these women is the subject of
a randomized trial of the National Cancer Institute and the Breast International
Group [25].
As outlined earlier, more loco-regional recurrences were observed after breast
conserving therapy. It can be expected that, due to improvement in patient selection
and treatment techniques, the differences will decrease between breast conserving
therapy and mastectomy, with regard to the occurrence of loco-regional recurrences
after breast conserving therapy [26]. This is also in accordance with the results of the
EORTC trial that randomised between a conventional therapeutic regimen and an
extra boost to the tumour bed after breast conserving surgery [27]. Local control was
significantly improved by adding a radiation boost for patients with breast
conservation.
This analysis shows that young age and breast conserving therapy are both
independent predictors for isolated loco-regional recurrences. To reach optimal local
control, young women and patients treated with breast conserving therapy should be
monitored closely to detect local breast cancer recurrences at an early stage.
Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy
06 Prfschrft JvdH Binnenwerk  23-04-2006  16:07  Pagina 104
105
References
1. Vicini FA, Kestin L, Huang R, et al. Does local recurrence affect the rate of distant metastases
and survival in patients with early-stage breast carcinoma treated with breast-conserving
therapy? Cancer 2003;97:910–9.
2. Harris EE, Hwang WT, Seyednejad F, et al. Prognosis after regional lymph node recurrence in
patients with stage I–II breast carcinoma treated with breast conservation therapy. Cancer
2003;98:2144–51.
3. Veronesi U, Marubini E, Del Vecchio M, et al. Local recurrences and distant metastases after
conservative breast cancer treatments: partly independent events. J Natl Cancer Inst
1995;87:19–27.
4. Fisher B, Anderson S, Fisher ER, et al. Significance of ipsilateral breast tumour recurrence
after lumpectomy. Lancet 1991;338:327–31.
5. Dongen JAv, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing
breast-conserving therapy with mastectomy: European Organisation for Research and
Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000;92:1143–50.
6. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing
total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of
invasive breast cancer. New Engl J Med 2002;347:1233–41.
7. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study
comparing breast-conserving surgery with radical mastectomy for early breast cancer. New
Engl J Med 2002;347:1227–32.
8. Arriagada R, Le MG, Guinebretiere JM, et al. Late local recurrences in a randomised trial
comparing conservative treatment with total mastectomy in early breast cancer patients.
Ann Oncol 2003;14:1617–22.
9. Elkhuizen PH, van de Vijver MJ, Hermans J, et al. Local recurrence after breast-conserving
therapy for invasive breast cancer: high incidence in young patients and association with
poor survival. Int J Radiat Oncol Biol Phys 1998;40:859–67.
10. Touboul E, Buffat L, Belkacemi Y, et al. Local recurrences and distant metastases after 
breast-conserving surgery and radiation therapy for early breast cancer. Int J Radiat Oncol
Biol Phys 1999;43:25–38.
11. Horst KC, Smitt MC, Goffinet DR, et al. Predictors of local recurrence after breast-
conservation therapy. Clin Breast Cancer 2005;5:425–38.
12. Huston TL, Simmons RM. Locally recurrent breast cancer after conservation therapy.
Am J Surg 2005;189:229–35.
13. Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant
recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer:
pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688–97.
14. Arriagada R, Le MG, Contesso G, et al. Predictive factors for local recurrence in 2006 patients
with surgically resected small breast cancer. Ann Oncol 2002;13:1404–13.
15. van Dongen JA, Bartelink H, Fentiman IS, et al. Randomized clinical trial to assess the value
of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer
Inst Monogr:15–8.
16. van Dongen JA, Bartelink H, Fentiman IS, et al. Factors influencing local relapse and survival
and results of salvage treatment after breast-conserving therapy in operable breast cancer:
EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II
breast cancer. Eur J Cancer 1992;28A:801–5.
Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy
06 Prfschrft JvdH Binnenwerk  23-04-2006  16:07  Pagina 105
106
17. Clahsen PC, van de Velde CJ, Julien JP, et al. Improved local control and disease-free survival
after perioperative chemotherapy for early-stage breast cancer. A European Organisation for
Research and Treatment of Cancer Breast Cancer Cooperative Group Study. J Clin Oncol
1996;14:745–53.
18. Elkhuizen PH, van Slooten HJ, Clahsen PC, et al. High local recurrence risk after breast-
conserving therapy in node-negative premenopausal breast cancer patients is greatly
reduced by one course of perioperative chemotherapy: a European Organisation for Research
and Treatment of Cancer Breast Cancer Cooperative Group Study. J Clin Oncol
2000;18:1075–83.
19. van der Hage JA, van de Velde CJ, Julien JP, et al. Improved survival after one course of
perioperative chemotherapy in early breast cancer patients. long-term results from the
European Organisation for Research and Treatment of Cancer (EORTC) Trial 10854.
Eur J Cancer 2001;37:2184–93.
20. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary
operable breast cancer: results from the European Organisation for Research and Treatment
of Cancer trial 10902. J Clin Oncol 2001;19:4224–37.
21. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data.
New York: Springer-Verlag; 2003.
22. Voogd AC, van Oost FJ, Rutgers EJ, et al. Long-term prognosis of patients with local
recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer
2005;41:2637–44.
23. Early Breast Cancer Trialists  Collaborative Group. Effects of radiotherapy and surgery in
early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists’
Collaborative Group. New Engl J Med 1995;333:1444–55.
24. Kroman N, Holtveg H, Wohlfahrt J, et al. Effect of breast conserving therapy versus radical
mastectomy on prognosis for young women with breast carcinoma. Cancer 2004;100:688–93.
25. National Cancer Institute and Breast International Group. Available from
www.nci.nih.gov/search/ViewClinicalTrials. aspx?cdrid=343619&version=Health
Professional&protocolsearchid=1537001.
26. Ernst MF, Voogd AC, Coebergh JW, et al. Using loco-regional recurrence as an indicator of the
quality of breast cancer treatment. Eur J Cancer 2004;40:487–93.
27. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer
with standard radiotherapy with or without additional radiation. New Engl J Med
2001;345:1378–87.
Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy
06 Prfschrft JvdH Binnenwerk  23-04-2006  16:07  Pagina 106
107
Part III
06 Prfschrft JvdH Binnenwerk  23-04-2006  16:07  Pagina 107
108
06 Prfschrft JvdH Binnenwerk  23-04-2006  16:07  Pagina 108
109
CHAPTER 8
Impact of established prognostic factors in
early stage breast cancer in very young breast
cancer patients; a translational research project
using pooled datasets derived from 4 EORTC
Breast Group Trials
J.A. VAN DER HAGE, C.J.H. VAN DE VELDE, H. PUTTER, H. BARTELINK, M.J. VAN DE VIJVER,
ON BEHALF OF THE EORTC BREAST CANCER GROUP
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Abstract
Young age at time of diagnosis of breast cancer is an independent prognostic factor associated
with unfavorable outcome in terms of survival and locoregional control.This has led to the general
recommendation to administer adjuvant systemic chemotherapy to patients aged 35 years or less
at time of diagnosis regardless of other tumor characteristics like tumor size and axillary lymph
node status.
However, since breast cancer at a very young age, i.e. < 41 years is a relative rare event, evidence
concerning prognostic factors within this subgroup of patients is lacking. Therefore the data of
four EORTC Breast Group Trials concerning primary operable breast cancer were combined to
study prognostic factors on long term outcome in very young breast cancer patients. The total
dataset consisted of 9938 early breast cancer patients. Tumor material was collected from 
549 patients aged under 41 years of age at time of diagnosis. In the multivariate analyses, only
histological grade remained a significant prognostic factor for both overall survival (Grade II HR
2.67; 95% CI 0.91 to 7.80; P = 0.07, Grade III HR 3.92; 95%CI 1.38 to 11.16; P = 0.01) and distant
metastasis free survival (Grade II HR 2.04; 95% CI 1.07 to 3.88; P = 0.03, Grade III HR 2.38; 95%CI 1.29
to 4.39; P < 0.01). However, large tumor size remained an independent unfavorable prognostic
factor on outcome in terms of distant metastasis free survival as well (HR 1.64 (1.17-2.31) P < 0.01).
In the subgroup of node negative very young breast cancer patients, histological grade remained
an independent prognostic factor for both overall survival (Grade III HR 8.92; 95%CI 1.17 to 68.20;
P = 0.04) and distant disease-free survival respectively (Grade III HR 4.12; 95%CI 1.42 to 11.98;  
P < 0.001). Histological grade is a strong independent prognostic factor, even in young breast
cancer patients. These findings support the fact that histological grade is an excellent diagnostic
tool to assess disease outcome in this specific subset of very young breast cancer patients.
Introduction
The incidence of early stage breast cancer in very young women is increasing. At
present breast cancer at young age, i.e. under age 35, does account for approximately
5% of the total number of cases diagnosed each year in the US.
Based upon multiple retrospective analyses demonstrating the independent
unfavorable prognostic impact of young age on prognosis in breast cancer, current
consensus guidelines have included young age (< 35) as an absolute indication for
adjuvant systemic chemotherapy after primary removal of the tumor irrespective of
other tumor characteristics [1-4]. Such guidelines imply that young patients with
favorable tumor features such as small tumor size and a negative axillary nodal
status will receive chemotherapy as well although absolute treatment benefits for
these patients are not well known which is the result of the fact that breast cancer at
very young age remains a relatively infrequent event.
Retrospective analyses have demonstrated breast cancer at a very young age to be
associated with higher grade, ER negative tumors and later stage disease at time of
diagnosis [5,6].
However, other yet unknown factors may be responsible for the poorer outcome in
this subset of patients and this hypothesis is emphasized by the fact that BRCA I and
II mutation carriers only account for 10% in this population [7-9].
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Therefore, two questions remain still very much open for discussion to date. First, do
all very young breast cancer patients require adjuvant systemic chemotherapy, and
second, by which means can subsets of patients within this group of very young
women be identified who have an excellent or poor prognosis.
To study these questions we pooled the data of four randomized trials conducted by
the EORTC Breast Cancer Group and the EORTC radiotherapy Group and collected
tumor material of patients under age 41 who participated in one of these trials.
Patients and Methods
The data used in this study was obtained from 4 randomized phase III EORTC trials that
included patients with early stage breast cancer. Two trials randomized between two
types of locoregional therapy whereas two trials randomized between different timing of
the same type of systemic therapy. The detailed features of these trials have been
described in detail previously (ref). In summary, the trial protocols are listed below:
EORTC trial 10801 (1980-1986, median follow up 13.4 years) was conducted in order to
assess the safety of breast conserving treatment. In this trial, patients were
randomized between breast conserving surgery combined with radiotherapy and
radical mastectomy. Six cycles of adjuvant chemotherapy with cyclophosphamide 
100 mg/m2 given orally on days 1-14, methotrexate 40mg/m2 given intravenously on
days 1 and 8, and 5-fluorouracil 600 mg/m2 given intravenously on days 1 and 8, were
indicated for all patients under the age of 55 with positive nodes. No information was
collected on hormonal therapy. In this study, 902 patients were randomized [10].
EORTC trial 10854 (1986-1991, median follow up 10.8 years) studied the question
whether one course of peri-operative chemotherapy given directly after surgery yields
better results in terms of treatment outcome than surgery alone. Peri-operative
chemotherapy consisted of one single course of doxorubicin 50 mg/m2, 5-fluorouracil
600 mg/m2, and cyclophosphamide 600 mg/m2 (FAC), administered intravenously
within 36 hours after surgery. Axillary lymph node-positive premenopausal patients
in the peri-operative chemotherapy group were recommended to receive an extra 
5 cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). Node-positive
patients, younger than 50 years, who did not receive peri-operative chemotherapy,
were advised to give one conventional course of FAC followed by five cycles of CMF
after surgery. Patients were stratified for breast conserving therapy and modified
radical mastectomy. Prolonged adjuvant systemic treatment was left to the discretion
of the local investigators. 2795 patients were included in this trial [11].
EORTC trial 10902 (1991-1999, median follow up 6.1 years) was set up to determine the
value of pre-operative chemotherapy. Patients were randomized to receive four cycles
of chemotherapy either before or after surgery. Chemotherapy consisted of four cycles
of 5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, and cyclophosphamide 
600 mg/m2 (FEC) administered intravenously, at 3-weekly intervals. In the pre-
operative chemotherapy group, surgical therapy followed within four weeks of the
fourth course of chemotherapy. In the postoperative chemotherapy group, the first
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cycle was given within 36 hours
after surgery. Stratification was
performed for planned type of
surgery instead of performed
type of surgery. This was done
because of the expected effect
of pre-operative chemotherapy
on downstaging of the tumor.
A total number of 698 patients
were randomized [12].
EORTC trial 22881 (1989 – 1996,
median follow up 5.1 years)
studied the value of a boost
dose after primary breast
conserving surgery. Patients
with breast cancer of clinical
stage T1–2,N0–1,M0 were eligible
for the trial. Patients with stage
I or II breast cancer who had
undergone macroscopically complete surgical removal of the tumor and axillary
dissection were randomly assigned to undergo 50-Gy irradiation of the whole breast
with or without an additional dose of 16 Gy to the tumor bed. Patients with a
microscopically incomplete excision were assigned to receive booster doses of 10 or
26 Gy. Patients with axillary lymph-node involvement received adjuvant systemic
therapy: premenopausal patients received chemotherapy, and postmenopausal
patients received tamoxifen. Patients not given adjuvant chemotherapy began
radiotherapy within nine weeks after lumpectomy. For patients who received
adjuvant chemotherapy, a delay of up to six months before irradiation was allowed.
This study enrolled 5569 patients [13].
In all trials if adjuvant chemotherapy was indicated, patients either received CMF or
an anthracyclin-based regimen (FAC or FEC). Adjuvant hormonal therapy for
premenopausal ER or PgR positive patients was not yet recommended at the time
when these trials were conducted. No information concerning estrogen receptor
status and tamoxifen use was available for patients who participated in EORTC trial
10801. In the trials where tamoxifen use was recorded, less than 5% of patients ≤ 41
years received tamoxifen.
Collection of tumor material and immunohistochemistry
A questionnaire was send to participating institutions to collect paraffin tumor
specimens from all patients aged under 41 at time of diagnosis except for those who
had participated in EORTC trial 10902 and received neoadjuvant chemotherapy. Tumor
tissue was collected and processed for immunohistochemistry using a tissue
microarray. Three core biopsies were taken from every tumor specimen and put in a
so-called donor block. On average, one tissue array donor block consisted of three
biopsies from sixty tumor specimens. This procedure has been described in debt by
others previously [14-17].
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Histological grading, scoring of the extent of intraductal carcinoma and lymph vessel
invasion was performed on H&E colored slides according to Bloom and Richardson
[18,19]. ER, PgR, Her2 and P53 expression levels were estimated by immuno-
histochemistry. Detailed procedures have been described previously [20-22]. In
summary, a tissue microarray slide was stained and scored counting the percentage
of positive nuclei and taking the mean value of the three tumor biopsies. For
estrogen- and progesterone receptor expression, Tumors with >10% of the tumor cells
showing nuclear staining were considered positive. Tumor were deemed p53 positive
if there was  > 50% nuclear staining. Her2 expression was scored estimating the level
of membranous staining. Strong membranous staining in > 10% of tumor cells was
considered positive. Estimation of tumor grade and protein expression levels were
scored by two investigators (MJ vd V & JA vd H) simultaneously who had to come to
an agreement in case of different views.
Selection of endpoints
Since this study was set up to study the impact of potential prognostic factors in very
young breast cancer patients on long term outcome, endpoints studied were overall
survival and distant metastasis free survival. Survival time was defined as the time
between randomization and death from any cause. Distant metastasis free survival
time was defined as time to distant metastasis or death if the latter event occurred
before a distant metastasis was diagnosed. Breast cancer specific survival was not
included since exact information concerning the cause of death was lacking in three
out of four trials.
Statistical analyses
All analyses were performed for overall survival and distant metastasis free survival.
Apart from patient age, covariates included consisted of tumor-, and treatment
related characteristics. Tumor characteristics were tumor size, nodal status, tumor
grade, hormone receptor status, Her2 overexpression, p53 overexpression, and
lymphangio invasion. Treatment characteristics consisted of type of surgery and the
administration of chemotherapy. Tamoxifen use was not included because of the high
rate of missing data for this covariant. Cox proportional-hazard regression models
[23] were used to estimate hazard ratios with 95% confidence intervals. A 5 %
significance level was used and all tests are two-sided. Survival analyses were
performed using the Kaplan Meyer method [24].
Results
Patient characteristics
A total of 9938 early stage breast cancer patients participated in one of four trials. The
majority of these patients, i.e. approximately 67%, were node negative. In addition,
approximately 70% of the patients whose hormone receptor status was available had
estrogen receptor positive breast cancer. Further patient characteristics are listed in
Table I. 1192 patients were aged under 41 years at time of diagnosis. Paraffin
embedded tumor material was successfully obtained and processed into a tissue
micro array for 549 patients younger than 41 years. This subgroup of patients had
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similar characteristics in terms of
nodal status and hormone receptor
status as compared to the whole
group of patients. Patient
characteristics of this subgroup are
listed in Table 2. At time of the
analysis, 1837 patients have died
and 603 patients developed distant
disease and were still alive. The
median follow up period was 
7 years.
Young patients versus older patients
Univariate prognostic factor
analyses were performed using age
as a covariant to determine
whether age had significant
prognostic impact on disease
outcome in this patient population.
First, patients aged under 41 years
of age were compared with
patients older than 41 years and
secondly this group of patients was
further divided into three
subgroups; < 30 years, 31-35 years
and 36-40 years.
In the univariate analysis, age
under 41 was a significant
prognostic factor for overall
survival (HR 1.34 (1.18-1.52) P < 0.01) (Figure 1) and distant metastasis free survival
(HR 1.48 (1.33-1.65) P < 0 .01) associated with unfavorable prognosis. The unfavorable
prognostic impact was most profound in patients aged under 31 for overall survival
(HR 1.77 (1.25-2.51) P < 0.01) (Figure 2) and distant metastasis free survival (HR 2.16
(1.63-2.86) P < 0.01).
To test whether the observed prognostic impact of young would remain significant
when other tumor characteristics are taken into account, we first performed
univariate analyses for overall and distant metastasis free survival including tumor
size, nodal status, estrogen receptor status, type of surgery, and the administration of
adjuvant chemotherapy. To prevent potential confounding due to selection bias as a
result of the different trials in which patients participated; we also inserted trial as a
covariant. Trial 22881 was defined as reference trial. All the above mentioned
covariates were significantly associated with outcome for overall survival and distant
metastasis free survival (Table 3).
Next, we included all covariates, including patient age, into a multivariate analysis to
test the independent effect of age on outcome. Estrogen receptor status was not
included in the multivariate analysis since no information was available for 2942
patients including all patients who participated in EORTC trial 10801 and therefore
Impact of established prognostic factors in early stage breast cancer in very young breast cancer patients
Table 2. Patients < 41 years
06 Prfschrft JvdH Binnenwerk  23-04-2006  16:07  Pagina 114
115
these data would be lost. The prognostic impact of all covariates except type of
surgery remained significant (See table 3). Tumor size > 5cm and positive axillary
lymph nodes were strong prognostic factors for poor prognosis, risk ratio’s being 2.28
and 2.37 for overall survival and 2.25 and 1.97 for distant metastasis free survival
respectively. In addition, young age remained an independent prognostic factor for
overall (RR 1.43 (1.25-1.63) P < 0.01) and distant metastasis free survival (RR 1.58 (1.41-
1.77 P < 0.01).
Prognostic factor analyses within the young age group
Next, we studied the prognostic impact of several different tumor characteristics in
the subset of 549 patients aged under 41 of which tumor material was collected.
Patient characteristics and immunohistochemistry results are listed in Table 2. To test
whether these covariant had significant impact on prognosis in young breast cancer
patients, univariate analyses for overall survival and distant metastasis free survival
were performed. Large tumor size, positive nodal status, poorly differentiated
histological grade, extensive lymphangio invasion and negative hormone receptor
status were all associated with poor survival (Table 4). In addition, adjuvant chemo-
therapy was associated with poor outcome (HR 1.90 (1.34-2.71) P < 0.01). Her2 over
expression (HR 1.09 (0.70-1.69) P = 0.71) and P53 overexpression (HR1.53 (0.90-2.04) 
P = 0.15) were not significantly associated with poor overall survival in this group of
patients.
For distant metastasis free survival, large tumor size, nodal status, poorly
differentiated histological grade, and adjuvant chemotherapy were associated with
poor outcome (Table 4). Positive ER status (HR 0.90 (0.65-1.24) P = 0.51) did not have a
significant impact on distant metastasis free survival. Similar results were found for
progesterone receptor status. In addition, Her2 and P53 overexpression did not have a
significant impact on distant metastasis free survival.
Subsequently, we tested the independent significant covariates in the univariate
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survival analysis for the
endpoints overall survival and
distant metastasis free survival.
In the multivariate analysis we
selected tumor size as assessed
by pathological examination
and discarded clinical tumor
size.
In the multivariate analyses,
only histological grade
remained a significant
prognostic factor for both
overall survival and distant
metastasis free survival (Table
5). However, large tumor size
remained an independent
unfavorable prognostic factor on
outcome in terms of distant
metastasis free survival as well
(HR 1.64 (1.17-2.31) P < 0.01).
Node negative patients who did
not receive chemotherapy
Young versus Old
To detect whether differences in
prognosis between young and
older patients would still exist
in node negative patients, we
selected all axillary node
negative patients who had not
received adjuvant-prolonged
chemotherapy. This subgroup
consisted of 6060 patients of
whom characteristics are listed




both groups. Young age
remained of significant prognostic impact for patients bearing cT2 or cT3 tumors in
terms of distant metastasis free survival (Table 7). In terms of overall survival, young
age still showed a trend significant effect on outcome for smaller tumors but not for
larger tumors (Table 7).
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Prognostic factors within young
node negative patients
The subgroup of young node
negative patients of whom
tumor material was collected
consisted of 341 women. Patient
characteristics are listed in Table





status, Her2 status, P53 status,
and type of surgery and
chemotherapy. In the univariate
analyses, tumor size, grade and
hormone receptor status
demonstrated to be significant
prognostic factors on overall and
distant metastasis-free survival
(See Table 9).
Next, in the multivariate
analyses, histological grade
remained an independent
prognostic factor for both
overall survival (Gr II vs Gr I NS,
Gr III vs Gr I HR 8.92 (1.17-68.20)
P 0.04) and distant disease-free
survival respectively (Gr II vs 
Gr I NS, Gr III vs Gr I HR 4.12
(1.42-11.98) P <0.001). Further
results are listed in Table 10 and
univariate Kaplan Meyer curves
for overall survival and distant
disease free survival concerning
histological grade are depicted
in Figures 3 and 4.
Discussion
In this study we performed a
retrospective analysis to gain
further insight in tumor characteristics of young breast cancer patients. Young age at
onset of breast cancer is a well-known independent prognostic factor but a
genotypical explanation for this phenomenon is still lacking. Part of the more
aggressive behavior of breast cancer at a young age may be attributable to hereditary
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prolonged CT (N= 6060)
Table 7. Multivariate analyses node negative patients who
did not receive prolonged CT
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factors. However, at present
only approximately 10% of
young breast cancer cases have
a documented BRCA I or BRCA II
mutations or have a strong
positive family history of breast
cancer [7-9, 25].
We demonstrated in approxi-
mately 10000 early stage breast
cancer patients that age > 41
years is a strong prognostic
factor on disease outcome
independent of other covariates.
This is in accordance with
previous data, which have led to
the recommendation that all
patients aged ≤ 35 years at time
of diagnosis should receive
adjuvant chemotherapy
irrespective of other tumor
characteristics. In this study the
effect was most profound for
patients aged under 31.
However, the finding that
patients aged between 35 and
41 still had a poor prognosis
compared to older patients as
well could raise the question
whether or not these patients
should also receive adjuvant
chemotherapy.
In the subgroup of node
negative patients who did not
receive prolonged adjuvant
chemotherapy the prognostic
effect of young age was less
clear. In terms of overall
survival, young age as a
prognostic factor failed to reach
statistical significance. However,
there was a significant effect on distant disease free survival. Hazard ratios varied
between 1.13 and 1.50 in these analyses which could be roughly converted in NNT’s
(numbers needed to treat) varying between 11 and 38 hypothesizing an expected 30%
event rate at 10 years. In addition, in this study young node negative patients bearing
grade I tumors had excellent 10 years survival and distant disease-free survival rates
of approximately 90% for both endpoints.
This raises the discussion whether or not all young node negative patients should
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receive chemotherapy. Probably
two subgroups can be defined
comprising young patients who
do not require adjuvant
chemotherapy. First, young early
breast cancer patients who have
an excellent prognosis and
second patients with
chemotherapy-resistant tumors
who do not benefit from
chemotherapy anyway. Current
research using microarray based
prognostic and predictive risk
models [26-28] may further elucidate this challenge of so-called treatment tailoring.
In this study, histological grade was the strongest prognostic factor of the covariates
studied, distinguishing young patients with a favorable prognosis from young
patients with an unfavorable prognosis. The majority of young patients had grade III
tumors (53%). In addition, large tumor size remained an independent risk factor for
distant disease free survival as well. Axillary nodal status was a prognostic factor in
the univariate analyses but did not remain significant in the multivariate analyses.
Her 2 overexpression and p53 overexpression failed to be of prognostic significance in
this subset of young patients. This is not in accordance with previous reports [29, 30].
Maru et reported a positive p53 status in 22 of 44 patients (50%), and a positive HER-
2/neu status in 18 of 41 patients (44%) scored by FISH. In our study, the p53 and Her 2
positive rates were 29% and 26% respectively estimated by immunohistochemistry.
Although Her2 overexpression is a well-known risk factor associated with poor
prognosis, we were not able to demonstrate a significant effect. This could be due to
insufficient sample size since only 121 patients had Her2 overexpressing tumors
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Figure 3. Overall survival and grade Figure 4. Distant disease-free survival and
grade
06 Prfschrft JvdH Binnenwerk  23-04-2006  16:07  Pagina 119
120
estimated by immunohistochemistry. It may also be due to other unknown factors in
young breast cancer patients, which result in a more aggressive genotype, which is
much less influenced by Her2 expression. These plausible unknown factors yet have
to be discovered [31].
In conclusion, well known established prognostic factors as tumor size and histologic
grade still remain independent prognostic factors on disease outcome in young breast
cancer patients and therefore can be a valuable tool in patient information and
education. Treatment guidelines concerning young breast cancer patients should be
refined in the future based on tumor characteristics, probably derived from
microarray driven translational research projects, and not based upon age alone.
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CHAPTER 9
Efficacy of adjuvant chemotherapy 
according to hormone receptor status 
in young breast cancer patients
J.A. VAN DER HAGE, M.J. VAN DE VIJVER, P. THERASSE, C.J.H. VAN DE VELDE,
AND COOPERATING INVESTIGATORS OF THE EUROPEAN ORGANIZATION FOR RESEARCH
AND TREATMENT OF CANCER (EORTC)
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Abstract
Breast cancer at a young age is associated with an unfavorable prognosis. We studied the effect of
adjuvant chemotherapy in young breast cancer patients in relation to hormone receptor status.
Paraffin embedded tumor material was collected from 480 early stage breast cancer patients
younger than 41 years who participated in one of four EORTC trials. Estrogen receptor- and
progesterone receptor status were assessed using immunohistochemistry.. The median follow up
period was 7.3 years. Patients that received chemotherapy did not have significant differences in
OS (HR 0.87, P = 0.63) and DMFS (HR 1.36, P = 0.23) rates according to ER status. Patients with 
ER-positive tumors who did not receive adjuvant chemotherapy had better OS (HR 0.41, P < 0.01)
and DMFS (HR 0.59, P = 0.02) rates than those with ER-negative tumors. Patients with ER-positive
tumors benefit less from adjuvant systemic chemotherapy than patients with ER-negative tumors.
These differences were similar for PgR status. In conclusion, young patients with ER positive
tumors seem to benefit less from adjuvant systemic chemotherapy than patients with ER negative
tumors.
Introduction
Breast cancer in premenopausal women is associated with worse outcome compared
to postmenopausal patients [1]. Approximately 7% of women diagnosed with breast
cancer are aged below 40 years [2]. Especially very young women, i.e. < 35 years are at
a high risk of developing distant metastases and therefore are recommended to
receive adjuvant systemic chemotherapy regardless of tumor stage [3]. In addition,
high local regional recurrence rates after breast conserving therapy have been
reported in young premenopausal breast cancer patients [4]. Although it is clear that
young age is an independent prognosticator of adverse outcome in breast cancer,
controversies exist regarding the optimal treatment in this population.
Adjuvant systemic chemotherapy in premenopausal patients has been shown to
improve survival [5], but controversy still exists about the role of chemotherapy in
hormone receptor positive patients. Since chemotherapy alone in estrogen receptor
(ER) and/or progesterone receptor (PgR)- positive breast cancer patients may not be
sufficient [6], several trials in premenopausal ER and/or PgR- positive breast cancer
patients have studied the role of ovarian ablation using LHRH-analogues [7,8,9,10].
One study by Aebi et al. [6] very clearly showed that the endocrine effects of
chemotherapy alone might not be sufficient for very young breast cancer patients. In
this study, it was shown that estrogen receptor positive tumors in patients younger
than 35 years and treated with CMF had a significantly worse disease-free survival
compared to estrogen receptor negative patients.
To detect whether we could confirm these data by finding similar results, we studied
the efficacy of chemotherapy in young breast cancer patients according to estrogen
receptor and progesterone receptor status, we selected patients younger than or
equal to 40 years of age at time of primary diagnosis from 4 European Organization
for Research and Treatment of Cancer (EORTC) trials, 10801, 10854, 10902, and 22881,
that were conducted by the EORTC Breast Cancer- and Radiotherapy Group.
Efficacy of adjuvant chemotherapy according to hormone receptor status in young breast cancer patients
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Patients and Methods
Data was collected from four EORTC trials. In total, 9938 patients participated in these
trials and 934 of these patients were younger or equal to 40 years of age at time of
diagnosis. The trial designs are summarized below:
EORTC trial 10801 (1980-1986, median follow up 13.4 years) was conducted in order to
assess the safety of breast conserving treatment. In this trial, patients were
randomized between breast conserving surgery combined with radiotherapy and
radical mastectomy. Six cycles of adjuvant chemotherapy with cyclophosphamide 100
mg/m2 given orally on days 1-14, methotrexate 40mg/m2 given intravenously on days
1 and 8, and 5-fluorouracil 600 mg/m2 given intravenously on days 1 and 8, were
indicated for all patients under the age of 55 with positive nodes. In this study, 902
patients were randomized [11].
EORTC trial 10854 (1986-1991, median follow up 10.8 years) studied the question
whether one course of peri-operative chemotherapy given directly after surgery yields
better results in terms of treatment outcome than surgery alone. Peri-operative
chemotherapy consisted of one single course of doxorubicin 50 mg/m2, 5-fluorouracil
600 mg/m2, and cyclophosphamide 600 mg/m2 (FAC), administered intravenously
within 36 hours after surgery. For axillary lymph node-positive premenopausal
patients in the peri-operative chemotherapy group adjuvant chemotherapy consisting
of 5 cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) was
recommended. For node-positive patients younger than 50 years who did not receive
peri-operative chemotherapy, one conventional course of FAC followed by five cycles
of CMF after surgery was recommended. Postmenopausal patients were
recommended to receive tamoxifen. 2795 patients were included in this trial [12].
EORTC trial 10902 (1991-1999, median follow up 6.1 years) was set up to determine the
value of pre-operative chemotherapy. Patients were randomized to receive four cycles
of chemotherapy either before or after surgery. Chemotherapy consisted of four cycles
of 5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, and cyclophosphamide 600 mg/m2
(FEC) administered intravenously, at 3-weekly intervals. In the pre-operative
chemotherapy group, surgical therapy followed within four weeks of the fourth
course of chemotherapy. In the postoperative chemotherapy group, the first cycle was
given within 36 hours after surgery. Patients ≥ 50 years received tamoxifen for 2 years.
A total number of 698 patients were randomized [13].
EORTC trial 22881 enrolled 5569 patients between 1989 and 1996. Stage I/ II breast
cancer patients were randomized between to undergo 50 Gy irradiation of the whole
breast with or without an additional dose of 16 Gy to the tumor bed after
lumpectomy. Patients with a microscopically incomplete resection were assigned to
receive a boost dose of 10 Gy or 26 Gy. Premenopausal patients with axillary lymph
node involvement received chemotherapy and postmenopausal patients received
tamoxifen [14].
In all trials if adjuvant chemotherapy was indicated, patients either received CMF or
Efficacy of adjuvant chemotherapy according to hormone receptor status in young breast cancer patients
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an anthracyclin-based regimen
(FAC or FEC). Adjuvant
hormonal therapy for
premenopausal hormone
receptor positive patients was
not yet recommend at the time
when these trials were
conducted. In the oldest two
trials tamoxifen administration
was not even recorded. This
explains the high number of
patients for which no
information was found on
tamoxifen use. In the trials
where tamoxifen use was
recorded, less than 5% of
patients ≤ 41 years received
tamoxifen.
ER staining and PgR staining
Paraffin embedded tumor
material was collected from 549
patients ≤ 40 years. Tumors
were histologically graded using
H&E slides as described
previously [15].
Immunohistochemical staining for estrogen receptor and progesterone receptor
status was performed using a tissue micro array [16,17,18,19]. Three core biopsies
were taken from each tumor block and inserted into a donor block. Immuohisto-
chemical staining for estrogen receptor was performed using the monoclonal
antibody DAKO-ER, 1D5 (Dakopatts, Glostrup, Danmark); for progesterone receptor
using the monoclonal antibody mPRI (TRANSBIO, Paris, France. Immunohistochemical
staining was scored using a semiquantative system based on the percentage of
positive nuclei. After counting the percentage of positive nuclei in three core biopsies
the mean value was taken. For estrogen- and progesterone receptor, tumors with
>10% of the tumor cells showing nuclear staining were considered positive.
Statistical analysis
Analyses were performed for distant metastasis-free survival (DMFS) and overall
survival (OS). Distant metastasis-free survival was defined as the interval from time
of randomization until time of distant metastasis or death, whichever event came
first. Overall survival was defined as time from randomization to death from any
cause. Survival curves were estimated using the Kaplan-Meier method [20].
Differences in survival were analysed using Cox proportional hazard models [21]. All
statistical analyses were performed using SPSS software. A direct comparison of
patients who received chemotherapy versus patients who did not receive
chemotherapy per hormone receptor status group was not feasible since this would
Efficacy of adjuvant chemotherapy according to hormone receptor status in young breast cancer patients
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introduce a selection bias in
this retrospective analysis. This
due to the fact that the vast
majority of patients receiving
chemotherapy had positive
axillary lymph nodes. Therefore,
conclusions in this explorative




specimens were collected for
480 patients ≤ 40 years at time
of diagnosis. Patient
characteristics are listed in
Table 1. For 12 patients, ER
status could not be scored and
for 16 patients PgR status could
not be scored. 288 patients were
deemed ER positive whereas 223
patients were PgR positive.
Two hundred patients received
prolonged adjuvant systemic
chemotherapy and 279 patients
did not receive adjuvant
systemic chemotherapy. Ninety-
four percent of patients that did
not receive chemotherapy were
node-negative and eighty-five
percent of patients that did
receive chemotherapy were node-positive. Characteristics related to adjuvant
systemic chemotherapy treatment are listed in Table 2.
At time of the analysis, 102 patients had died and 150 patients developed a distant
recurrence or died. The number of events stratified by estrogen receptor status is
listed in Table 3. The median-follow-up period at time of analysis was 7,3 years.
Overall, patients with ER-positive tumors had better OS rates compared to ER-
negative patients, (HR 0.63, 95%CI 0.43 - 0.93, P= 0.02, Figure 1). Survival rates after a
median follow up of 7 years were approximately 82% for the ER positive group and
77% for the ER negative group. DMFS rates were 70% and 66% respectively which was
not statistically significant (HR 0.90, 95% CI 0.65 - 1.24, P =  0.51, Figure 2).
Progesterone receptor status yielded similar results in terms of overall survival and
distant metastasis-free survival. Patients with progesterone positive tumors had
better OS (HR 0.59, 95%CI 0.4 - 0.88, P = 0.01) but for DMFS this difference was not of
statistical significance (HR 0.78, 95%CI 0.57 - 1.01, P = 0.14).
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Patients that did not receive prolonged adjuvant chemotherapy
Estrogen receptor status
In the subset of patients that did not receive adjuvant systemic chemotherapy,
positive ER status was associated with better OS (HR 0.41, 95%CI 0.23 - 0.74, P < 0.01,
figure 3). Survival rates at 7 years were 90% for the ER positive group and 77% for the
Efficacy of adjuvant chemotherapy according to hormone receptor status in young breast cancer patients
Figure 1. Overall survival for all patients Figure 2. Distant metastasis-free survival for 
all patients
Figure 3. Overall survival in patients who did
not receive adjuvant chemotherapy
Figure 4. Distant metastasis-free survival in
patients who did not receive adjuvant
chemotherapy
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ER negative group. DMFS rates in the subset of patients that did not receive adjuvant
systemic chemotherapy were significantly better for ER positive patients as well, 80%
and 64% respectively (HR 0.59, 95%CI 0.37 - 0.92, P = 0.02, figure 4).
Progesterone receptor status
PgR positive patients who did not receive adjuvant chemotherapy had better OS (HR
0.44, 95%CI 0.24 - 0.8, P < 0.01). OS rates were 88% and 75% for ER positive and ER
negative patients. DMFS rates were 79% for PgR positive patients and 67% for PgR
negative patients respectively. However, this difference did not reach statistical
significance (HR 0.66, 95%CI 0.42 - 1.04, P = 0.07).
Patients who received prolonged adjuvant systemic chemotherapy
Estrogen receptor status
In the group of two hundred patients that did receive adjuvant systemic chemo-
therapy treatment outcome was not significantly different between ER positive- and
ER negative breast cancer patients. OS rates were 70% for the ER positive group and
75% for the ER negative group (HR 0.87, 95%CI 0.50 - 1.52, P = 0.63, figure 5) and DMFS
rates were 59% for the ER positive group and 70% for the ER negative group (HR 1.36,
95% CI 0.82 - 2.26, P = 0.23, figure 6).
Progesterone receptor status
Patients who had PgR negative tumors and received adjuvant systemic chemotherapy
did not have significant differences in terms of OS and DMFS rates. Both in the PgR
positive and PgR negative patient group, OS was 72% at 7 years of follow up (HR 0.84,
95%CI 0.49 - 1.43, P = 0.51). DMFS did not differ significantly between PgR positive
Efficacy of adjuvant chemotherapy according to hormone receptor status in young breast cancer patients
Figure 5. Overall survival in patients who
received adjuvant chemotherapy
Figure 6. Distant metastasis-free survival in
patients who received adjuvant chemotherapy
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patients and PgR negative patients who received adjuvant chemotherapy. DMFS rates
were 59% for the PgR positive group and 64% for the ER negative group (HR1.02, 95%CI
0.65 - 1.6, P = 0.93).
Multivariate analysis
Multivariate Cox regression overall survival analyses were performed for ER status
and PgR status separately. Other covariates included nodal status, tumor size, and the
administration of prolonged adjuvant chemotherapy. Both ER status (RR 1.65) and PgR
(1.56, data not shown) status remained independent prognostic factors with a
significant impact on overall survival (Table 4).
Discussion
Adjuvant systemic chemotherapy is a well-established treatment modality in
premenopausal breast cancer. In patients younger or equal to 35 years, chemotherapy
is advocated regardless of nodal status and tumor size and grade [3]. However, several
reports have questioned the efficacy of chemotherapy in premenopausal patients
with ER-positive breast cancer [6,7,10].
We demonstrated that ER–positive and/or PgR positive patients ≤ 40 years who
received prolonged adjuvant chemotherapy showed no advantage in treatment
outcome compared with ER-/PgR-negative patients, whereas ER-/PgR- positive
patients who did not receive adjuvant chemotherapy had better overall survival rates
compared with their ER-/PgR- negative counterparts. In terms of survival, figure 5
even suggests that the proportional hazards assumption is not justified in the
assessment of the effect of chemotherapy according to hormone receptor status.
Therefore we conclude that treatment efficacy of adjuvant chemotherapy is less in
young hormone receptor positive patients compared to young hormone receptor
negative patients. We did not perform direct comparisons between patients who
received chemotherapy versus patients who did not receive chemotherapy according
to hormone receptor status. Axillary lymph node status would have induced a
confounding error and since the majority of patients that did receive chemotherapy
also had positive axillary lymph nodes. Hormone receptor status therefore, may not
have been of significant impact on outcome in this subgroup.
However, in the multivariate analysis including ER status, axillary lymph node status,
tumor size and the administration of prolonged adjuvant chemotherapy, ER status
remained an independent prognostic factor for overall survival (RR1.65, 95%CI 1.09 -
2.5 P = 0.02, Table 4). Since these patients participated in trials in which adjuvant
tamoxifen was not routinely given to hormone receptor positive premenopausal
patients, less than 5% of the study population received tamoxifen, the effect of
adjuvant tamoxifen could not be measured.
Similar findings were recorded if ER status was replaced by PgR status (RR 1.56,
95%CI 1.02 - 2.39, P = 0.04).
We realize that this is a retrospective analysis using heterogeneous data from
different randomized trials and therefore any conclusions have to be drawn with
Efficacy of adjuvant chemotherapy according to hormone receptor status in young breast cancer patients
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caution. Preferably, we should
have liked to compare
chemotherapy versus not in
hormone receptor positive
patients and then compare
chemotherapy versus not in
hormone receptor negative
patients. However, since this is
not a randomized comparison,
the confounding effect of
axillary lymph node status
would have induced a
significant selection bias. On the other hand, our findings are in accordance with data
from Aebi et al. [6] who demonstrated that young premenopausal breast cancer
patients treated with adjuvant CMF chemotherapy had a higher risk of relapse and
death than older premenopausal patients, especially if their tumors were ER-positive.
In this study, ER was assessed using a ligand-binding assay; in our study ER has been
assessed using immunohistochemistry. By analyzing ER status centrally, we have
provided standardized ER measurements for all tumors in the study.
In order to optimize adjuvant systemic treatment in premenopausal breast cancer
patients, several investigators have studied the role of ovarian suppression by LHRH
agonists.
The Zoladex‰ Early Breast Cancer Research Association (Zebra) trial [7,8] compared
goserelin and CMF in1640 node-positive, premenopausal and perimenopausal
patients, aged 50 years or less, with early breast cancer. After a median follow-up of 
6 years, goserelin and CMF showed equivalent disease-free survival rates in ER
positive patients (HR 1.01, 95%CI 0.84 - 1.20). However in the ER negative subgroup, a
significant advantage in favor of CMF was found (HR 1.76, 95%CI 1.27 - 2.44). A recent
update of the analysis demonstrated similar results. In addition, patients who
received LHRH agonists suffered less from treatment related side effects than
patients who received chemotherapy [22].
Other trials studying the effect of goserelin with or without tamoxifen versus CMF in
premenopausal hormone receptor positive breast cancer patients also demonstrate
equivalent or even better disease-free survival rates but this has not yet resulted in
better overall survival rates [23,24].
Although these results underline the fact that chemotherapy may be equivalent to
hormonal ovarian suppression in terms of treatment outcome in ER positive patients,
these results fail to demonstrate a superior effect of LHRH agonists over adjuvant
chemotherapy.
In conclusion, we have demonstrated in a subset of patients aged 40 years or less at
time of diagnosis that hormone receptor status is an independent prognostic factor
on distant metastasis-free survival and overall survival. Moreover, we showed that
hormone receptor status influences response to chemotherapy. Therefore, we can
conclude that chemotherapy alone is not sufficient hormone receptor positive young
breast cancer patients.
Efficacy of adjuvant chemotherapy according to hormone receptor status in young breast cancer patients
Table 4. Multivariate Cox overall survival regression
analysis
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This thesis consists of three parts.
In part I, we demonstrate that neoadjuvant and perioperative chemotherapy are very
feasible treatment options in early stage breast cancer patients. Both treatment
strategies result in equal or better results in terms of disease outcome as compared to
conventional postoperative adjuvant chemotherapy. In addition, the higher breast
conserving therapy rate after neoadjuvant chemotherapy described in Chapter 3 and
the potential to assess tumor response as a prognostic factor as stipulated in Chapter
4 are attractive characteristics of this type of treatment.
In part II, we demonstrate that locoregional treatment strategy may be based on
tumor cell characteristics and patient age. Next, we describe the significant impact of
adequate locoregional treatment on locoregional control as well as overall survival.
For example in Chapter 6, we show in a selected subgroup of patients bearing 1 to 3
metastatic axillary lymph nodes, that adjuvant radiotherapy after mastectomy was
associated with superior locoregional control and survival rates. In addition, in
Chapter 7 we attempt to identify baseline risk factors, i.e. factors assessed at time of
diagnosis of the primary tumor, for locoregional recurrence.
In part III, we demonstrate that very young breast cancer patients can be divided in
good- and bad prognosis groups based upon tumor characteristics. The current
guideline that all very young breast cancer patients should receive chemotherapy
irrespective of tumor characteristics can therefore be questioned. Next, we
demonstrate that tumor grade is a strong and independent prognostic factor for
distant metastasis-free survival and overall survival in this specific subgroup of very
young breast cancer patients. Finally in Chapter 9, a trend is described suggesting
inferior chemosensitivity in estrogen receptor (ER) positive and/or progesterone
receptor (PgR) positive very young breast cancer patients as compared to their ER and/
or PgR negative counterparts.
Breast cancer treatment is making progress. New therapies are introduced and
existing ones are further modified. One of these modifications is the result of studies
that focused on timing of administration of adjuvant systemic therapy which has
resulted into the introduction of neoadjuvant chemotherapy in the treatment of
breast cancer. Level I evidence is currently available for this type of treatment for both
locally advanced breast cancer patients and early stage breast cancer patients [1-3].
While survival and progression free survival have not yet been improved by
neoadjuvant chemotherapy in early breast cancer patients, breast conserving rates
have risen with acceptable locoregional control rates when surgery is not omitted
from the locoregional regime after neoadjuvant chemotherapy [1,4,5].
In the Netherlands however, neoadjuvant chemotherapy in early stage breast cancer
patients is still not being administrated on a routine basis although these patients
might definitely benefit from this treatment strategy. One of the potential reasons for
this conduct could be the reluctance of doctors to administrate systemic treatment
before definitive staging has been performed. However, the decision whether or not
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systemic chemotherapy will be indicated in a case of early breast cancer can to a
large extent very well be established by preoperative core needle biopsy and/or fine
needle aspiration of tumor and potential suspect axillary lymph nodes in
combination with physical examination and diagnostic imaging. In addition, the
indications for the administration of adjuvant chemotherapy have widened which
has resulted in a higher a priori probability for receiving chemotherapy. Therefore, a
shift in paradigm concerning treatment strategy of early breast cancer patients in the
Netherlands is needed.
Although the Dutch situation may cause some concern, research concerning
neoadjuvant treatment in breast cancer has gained a lot of interest and many trials
studying different neoadjuvant chemotherapy regimens are being conducted.
Research concerning neoadjuvant trials in early stage breast cancer should be
focused on four major topics:
1) Translational research. It is important to note that the response to neoadjuvant
chemotherapy in vivo could provide a useful prediction of prognosis and help define
strategies for an individual patient’s future treatment with alternative chemotherapy
regimens or molecular-targeting agents. Furthermore, the discovery of predictive
markers for tumor response to neoadjuvant chemotherapy through the analysis of
complementary DNA microarrays and proteomics may also help facilitate
individualized chemotherapy, particularly by improving survival in patients with
breast cancer with a poor prognosis. Therefore, translational research has to be
focussed on classical and molecular tumor characteristics and their response, i.e. up-
or downregulation, to established and experimental chemotherapeutic regimens and
the assessment of chemosensitivity in terms of tumor response [6,7].
2) Tumor monitoring modalities. Adequate assessment of tumor response and
pretreatment staging are vital in the neoadjuvant chemotherapy setting. Imaging of
tumor response has several implications; 
First, tumor response is considered as an independent prognostic factor on treatment
outcome and therefore should therefore be monitored meticulously [8].
Second, diagnostic modalities such as MRI and CT need to be prospectively evaluated
to study whether or not they yield superior results over classical ways of imaging like
ultrasonography and mammography. Breast MRI has been assuming an important
role in the assessment of the extent of cancer and may be more accurate than
conventional modalities such as mammography and ultrasonography. On the other
hand, MRI is associated with an increase in invasive therapeutic and diagnostic
procedures for benign abnormalities due to high false-positive rates. Therefore, MRI
may be feasible in a population of high risk patients but not in all early stage breast
cancer patients. In conclusion, the exact role of MRI in breast cancer and the
assessment of neoadjuvant chemotherapy needs to be determined [9-15].
Finally, imaging of tumor response is of significance considering optimalization of
subsequent breast conserving surgery. Tumor margins after neoadjuvant
chemotherapy have been a matter of concern. Tumor response does not always lead
to a decrease in tumor volume but can result in less tumor density. Although EORTC
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trial 10902 did not demonstrate a higher locoregional recurrence rate in downstaged
patients who underwent breast conserving surgery, meta-analyses which included
trials in which surgery was omitted after neoadjuvant chemotherapy demonstrated
inferior local control rates. Therefore the diagnostic preoperative assessment of
residual tumor after neoadjuvant chemotherapy is important [16,17].
3) Studies addressing the relation between locoregional treatment and neoadjuvant
chemotherapy, for instance the feasibility of sentinel node procedure after
neoadjuvant chemotherapy and quality of life studies concerning the psychological
effect of breast conserving therapy after tumor downstaging. Sentinel node biopsy
after neoadjuvant chemotherapy has been a matter of debate. Retrospective series
have demonstrated acceptable accuracy rates comparable to sentinel node biopsies in
the primary surgery setting. Recently, the first meta-analysis concerning sentinel
node biopsy after neoadjuvant chemotherapy has been published and the accuracy
rates in this study are in accordance with previous reports suggesting satisfactory
feasibility of this surgical treatment modality [18,19].
4) The efficacy of neoadjuvant hormonal therapy either by tamoxifen or by aromatase
inhibitors. With recent advances in endocrine therapy, and rapid and routine
assessment of predictive factors of response such as estrogen (ER), progesterone (PR)
and Her2 neu receptor status, endocrine therapy has come to the forefront of
research investigating a neoadjuvant alternative to chemotherapy. Early studies of
neoadjuvant endocrine therapy mainly evaluated the role of tamoxifen in the
treatment of elderly postmenopausal women with LABC who were unselected for
ER/PR status and who were unsuitable for either surgery or chemotherapy. Response
rates in these patients were found to be inferior to those traditionally obtained from
trials with neoadjuvant chemotherapy. Parallel to the superiority that third-
generation aromatase inhibitors have shown over tamoxifen in the metastatic and
adjuvant settings however, AIs have also demonstrated superiority in the neoadjuvant
setting. Recent studies have shown response rates for neoadjuvant treatment with
aromatase inhibitors in carefully selected hormone receptor positive patients to be
comparable to those seen with neoadjuvant chemotherapy. This is particularly
important as hormone receptor positive tumors have repeatedly been shown to have
lower response rates to neoadjuvant chemotherapy than hormone receptor negative
tumors [20-22].
Next, when neoadjuvant chemotherapy is not feasible and adjuvant chemotherapy will
be administrated postoperatively, the first course of chemotherapy can be given in a
perioperative setting which means that the patient receives the first course of
chemotherapy within 36 hours after surgery. Perioperative chemotherapy, as mentioned
previously in Chapter 2, is based principally upon evidence from murine models
demonstrating surgery-induced proliferation of tumor cells that responded well to early
administration of chemotherapy [23,24].
EORTC trial 10854, of which the long term results are presented in this thesis
demonstrated that this is a safe and feasible treatment modality which may have an
impact on locoregional control as well as on survival in selected groups of patients [25].
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Concerning locoregional therapy, different strategies should be employed in different
risk groups, for instance based upon age. Young breast cancer patients who are at a
high risk for locoregional recurrence, especially with histologically aggressive tumors
should be offered mastectomy with immediate or delayed reconstruction.
Locoregional control rates and patient satisfaction could be improved [26-29].
On the other hand, standard administration of chemotherapy in young patients with
node negative breast cancer can be questioned. Since risk ratios between young and
older breast cancer patients have moderate differences, subgroups within the young
age group could be identified where chemotherapy should not have been applied
irrespective of other patient and tumor characteristics. For instance, node negative
breast cancer patients bearing small grade I tumors have an excellent prognosis and
might not receive a clinically relevant benefit from adjuvant chemotherapy but they
do receive the burdens.
Thus, translational research concerning risk groups of young breast cancer patients
who might benefit from chemotherapy is needed. Recently, translational research has
been accelerated due to the introduction of micro-array analysis [30-33].
This highly promising technique using high throughput gene chips is not yet fully
validated but may enable treatment tailored strategies in the future. However, until
thorough validation of microarray is established and demonstrated, classical tumor
prognostic factors have to be used. Currently, neoadjuvant chemotherapy trials are
already being conducted with the incorporation of tumor markers in their study
design [34-36].
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In Chapter 1, a general introduction and an outline of the present thesis are given.
In Chapter 2, the eleven year follow up results of EORTC study 10854 are presented,
comparing one short intensive course of polychemotherapy (fluorouracil, doxorubicin,
cyclophosphamide; FAC) to no peri-operative chemotherapy in 2795 stage I en II
breast cancer patients, randomized between 1986 and 1991. Peri-operative
chemotherapy was associated with significant better progression free survival rates
(59% vs 53% without peri-operative chemotherapy) and locoregional control rates
(91% vs 86%) respectively. In the subgroup of patients that did not receive prolonged
systemic chemotherapy, one course of peri-operative chemotherapy led to significant
higher overall survival rates as well (HR=0.80; 95% CI: 0.64–0.98; P = 0.035).
In Chapter 3, the five-year results of EORTC study 10902 are presented, comparing
neoadjuvant anthracyclin based polychemotherapy versus the same chemo-
therapeutic regimen given postoperatively. EORTC trial 10902 randomized 698 patients
between 1991 and 1999. No significant differences between the two treatment arms
were observed for progression-free and overall survival. Overall survival after 5 years
was 82% in the preoperative group and 84% in the postoperative group (HR 1.16; 95%
CI: 0.83 to 1.63; P = 0.38). Progression-free survival rates after 5 years for the
preoperative and postoperative groups were 65% and 70%, respectively (HR 1.15; 95%
CI, 0.89 to 1.48; P = 0.27). Time to locoregional recurrence was not significantly
different between the two treatment arms (HR 1.13; 95% CI, 0.70 to 1.81; P = 0 .61).
In Chapter 4, the predictive role of p53 expression is studied in patients receiving
neoadjuvant chemotherapy. Using tumor response as a surrogate endpoint,
associations between p53 expression as well as other tumor markers like Her2 and
outcome were studied. Tumor biopsy specimens were taken from 107 patients prior to
the administration of neoadjuvant chemotherapy. In a multivariate logistic regression
analysis, pCR was independently predicted by p53 overexpression estimated by
immunohistochemistry (OR 16.83; 95% CI, 1.78 to 159.33; P = 0.01) and negative
pathological lymph node status (OR 8.47; 95% CI, 0.88 to 81.82; P = 0.07). In multi-
variate Cox regression analysis, positive pathological lymph node status and no use
of tamoxifen showed unfavourable prognosis for overall and distant disease-free
survival.
In Chapter 5, the potential prognostic impact of a putative tumor marker called PS6K
on locoregional recurrence is presented. The PS6K protein is encoded by the RPS6KB1
gene is located at chromosome and amplified in approximately 10% of all primary
breast cancer cases. PS6K is a protein that is involved in the cell cyclus. It is rapidly
activated in response to mitogenic stimuli, for example growth factors, cytokines, and
oncogene products. In a series of 452 node-negative premenopausal early-stage breast
cancer patients PS6K overexpression was associated both with worse distant disease-
free survival and with impaired locoregional control (HR 1.80, P = 0.025 and HR 2.50,
P = 0.006, respectively). In a multivariate analysis including other prognostic factors,
PS6K overexpression remained an independent predictor for poor locoregional control
(RR 2.67, P = 0.003). Therefore, PS6K could be a putative predictive and prognostic
factor to be used in the planning of less or more aggressive locoregional therapy.
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In Chapter 6, a retrospective analysis is presented concerning the impact of loco-
regional treatment on disease outcome. Breast-conserving surgery and mastectomy
with or without radiotherapy to the axilla and / or breast are compared in terms of
locoregional control and disease outcome. The combined data set consisted of 3648
patients. 5.9% of the patients who were treated with mastectomy and 10.8% of the
patients who were treated with breast-conserving therapy had a locoregional
recurrence (P < 0.0001). The risk of death after breast-conserving therapy was similar
compared with mastectomy (RR 1.07, P = 0.37). Adjuvant radiotherapy after
mastectomy was associated with a lower risk for locoregional recurrence (RR 0.43,
P < 0.001) and death (RR 0.73, P = 0.001). The effect of adjuvant radiotherapy after
mastectomy was most profound in patients who had 1–3 positive nodes (RR 0.48,
99% CI 0.31–0.75, P < 0.001).
In Chapter 7, risk factors for locoregional recurrence and the relationship between
locoregional recurrence and subsequent metastatic disease are studied in more
detail. To that end, different time intervals between locoregional recurrence and
subsequent metastatic disease are defined and compared in sensitivity analyses. The
study population comprised 3602 women who had undergone primary surgery for
early stage breast cancer. The results of multivariate analysis showed that younger
age and breast conservation were risk factors for isolated loco-regional recurrence;
breast cancer under 35 years of age versus over 50 years of age: HR 2.80 (95% CI 1.41
to 5.60); breast cancer age 35–50 years versus over 50 years: HR 1.72 (95% CI 1.17 to
2.54); breast conservation: HR 1.82 (95% CI 1.17 to 2.86). After perioperative
chemotherapy, less isolated loco-regional recurrences were observed (HR 0.63; 95% CI
0.44 to 0.91).
Therefore we hypothesised that, assuming an isolated loco-regional recurrence to be
a potentially curable condition, women treated with breast conservation or diagnosed
with breast cancer at a young age should be monitored closely to detect local
recurrence at an early stage.
In Chapter 8, a translational research project is presented concerning very young
breast cancer patients. The total dataset consisted of 9938 early breast cancer
patients. Tumor material was collected from 549 patients aged under 41 years of age
at time of diagnosis. In the multivariate analyses, only histological grade remained a
significant prognostic factor for both overall survival (Grade II HR 2.67; 95% CI 0.91 to
7.80; P = 0.07, Grade III HR 3.92; 95%CI 1.38 to 11.16; P = 0.01) and distant metastasis
free survival (Grade II HR 2.04; 95% CI 1.07 to 3.88; P = 0.03, Grade III HR 2.38; 95%CI
1.29 to 4.39; P < 0.01). However, large tumor size remained an independent
unfavorable prognostic factor on outcome in terms of distant metastasis free survival
as well (HR 1.64 (1.17-2.31) P < 0.01). In the subgroup of node negative very young
breast cancer patients, histological grade remained an independent prognostic factor
for both overall survival ( Gr III HR 8.92; 95%CI 1.17 to 68.20; P = 0.04) and distant
disease-free survival respectively (Gr III HR 4.12; 95%CI 1.42 to 11.98;  P < 0.001).
In Chapter 9, the efficacy of chemotherapy in early breast cancer is studied according
to hormone receptor status in patients aged less than 41 years. The median follow up
period was 7.3 years. Patients that received chemotherapy did not have significant
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differences in overall survival (HR 0.87, P = 0.63) and distant metastasis-free survival
(HR 1.36, P = 0.23) rates according to ER status. Patients with estrogen receptor (ER)
positive tumors who did not receive adjuvant chemotherapy had better overall
survival (HR 0.41, P < 0.01) and distant metastasis-free survival (HR 0.59, P = 0.02) rates
than those with ER-negative tumors. Therefore, it was concluded that very young
early stage breast cancer patients with ER-positive tumors benefit less from adjuvant
systemic chemotherapy than patients with ER-negative tumors. Similar results were
demonstrated for progesterone receptor status.
In Chapter 10, the results of this thesis are discussed within the scope of current
breast cancer therapy and research. Finally, suggestions are made concerning future
directions in translational and clinical breast cancer research.
Summary
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Dit proefschrift behelst een aantal klinische en translationele studies met betrekking
tot de behandeling van het primair operabel mammacarcinoom. Zowel aspecten van
de locoregionale behandeling als van de systemische behandeling worden belicht.
Alle hoofdstukken uit dit proefschrift zijn studies gebaseerd op EORTC onderzoeken.
In Hoofdstuk 1 wordt een overzicht van de geschiedenis van de behandeling van het
primair operabel mammacarcinoom gegeven en worden de rationales waarop dit
proefschrift is gebaseerd nader uiteengezet.
In Hoofdstuk 2 wordt een gerandomiseerde trial beschreven (EORTC trial 10854)
waarin het effect van een eenmalige gift polychemotherapie, gegeven direct na de
operatie, bij patiënten met primair operabel mammacarcinoom is bestudeerd. In
totaal participeerden bijna drieduizend patiënten in deze studie. Na een mediane
follow-up van elf jaar was er sprake van een significant betere ziektevrije overleving
alsmede een betere locoregionale controle voor alle patiënten die deze vorm van
zogenaamde perioperatieve chemotherapie ontvingen. Voor patiënten bij wie geen
verdere systemische behandeling werd gegeven leidde een eenmalige gift
perioperatieve chemotherapie zelfs tot betere overlevings-ratios.
In Hoofdstuk 3 worden de resultaten van EORTC trial 10902 gepresenteerd. Het betreft
een gerandomiseerde studie waarin het effect van neoadjuvant polychemotherapie
wordt vergeleken met postoperatieve polychemotherapie bij patiënten met primair
operabel mammacarcinoom. In totaal deden 698 vrouwen mee aan deze studie. Na
vijf jaar waren er geen verschillen tussen de experimentele en de controle arm in
deze studie wat betreft (ziektevrije-) overleving en locoregionale controle. Wel werden
patiënten die neoadjuvant chemotherapie ontvingen vaker mammasparend
geopereerd ten gevolge van zogenaamde “tumor downstaging”.
In Hoofdstuk 4 wordt een translationele studie gepresenteerd die de voorspellende
waarde bestudeert van “p53 expressie” op het effect van neoadjuvant chemotherapie.
Tumor materiaal van patiënten die participeerden in EORTC studie 10902 werd
verzameld en onderzocht middels immunohistochemie op de expressie van p53 en
Her2. Overexpressie van p53 en de afwezigheid van okselkliermetastasen waren
geassocieerd met een complete respons van de tumor op neoadjuvant chemotherapie
onafhankelijk van andere factoren. Ook was de aanwezigheid van okselklier-
metastasen na neoadjuvant chemotherapie een ongunstige prognostische factor wat
betreft (metastase vrije) overleving.
In Hoofdstuk 5 wordt de prognostische rol van een experimentele tumor marker, PS6K
genaamd, bestudeerd. Tumor weefsel van 452 patiënten met borstkanker zonder oksel-
kliermetastasen die participeerden in EORTC trial 10854 werd verzameld en onderzocht
middels immunohistochemie op overexpressie van dit eiwit dat een rol speelt bij de cel
cyclus. PS6K expressie was verhoogd bij patiënten met een slechte prognose wat betreft
metastase vrije overleving. Tevens was overexpressie van PS6K onafhankelijk van andere
factoren geassocieerd met een hoog locoregionaal recidief risico. De resultaten in dit
hoofdstuk onderschrijven de mogelijke rol van deze tumor marker bij het bepalen van
een meer of minder agressieve vorm van locoregionale behandeling.
Nederlandse samenvatting
06 Prfschrft JvdH Binnenwerk  23-04-2006  16:07  Pagina 148
149
In Hoofdstuk 6 wordt de rol van de locoregionale behandeling op de prognose bij
patiënten met primair operabel mammacarcinoom bestudeerd middels een
retrospectieve studie. De data van een drietal EORTC studies werden gecombineerd
(EORTC trials 10801, 10854, en 10902) en geanalyseerd. In totaal betrof het 3648
patiënten.
5.9% van de vrouwen die een mastectomie ondergingen versus 10.8% van de vrouwen
die een mammasparende operatie ondergingen kregen een locoregionaal recidief 
(P < 0.0001). Ondanks het verschil in locoregionale controle was de lange termijn
prognose (na correctie voor andere factoren) gelijk voor beide chirurgische
behandelingsmodaliteiten. Echter, het geven van adjuvant radiotherapie na
mastectomie was zowel geassocieerd met een betere locoregionale controle als met
een betere lange termijn prognose dan mastectomie zonder radiotherapie. Dit effect
was het meest opvallend bij patiënten met een beperkt aantal okselklier metastasen.
In Hoofdstuk 7 worden mogelijke risicofactoren voor het ontwikkelen van een
locoregionaal recidief en de prognostische impact van het locoregionale recidief  op
het ontwikkelen van metastasen op afstand nader bestudeerd. De studie populatie
bestond uit 3602 vrouwen met primair operabel mammacarcinoom. Uit multivariate
analyses bleken zowel jonge leeftijd als mammasparende chirurgie onafhankelijke
factoren voor het ontwikkelen van een locoregionaal recidief te zijn. Perioperatieve
chemotherapie was onafhankelijk geassocieerd met een lagere kans op het krijgen
van een locoregionaal recidief.
In Hoofdstuk 8 wordt een retrospectieve analyse gepresenteerd waarin risicofactoren
zijn geanalyseerd in een subgroep van zeer jonge vrouwen met primair operabel
mammacarcinoom. De data van 4 EORTC trials werden gecombineerd (EORTC trial
10801, 10854, 10902, 22881). In totaal participeerden 9938 vrouwen in deze studies.
Ongeveer 10 % van de vrouwen was 40 jaar of jonger ten tijde van de diagnose. Van
549 van deze jonge vrouwen was tumor materiaal beschikbaar. De mate van expressie
van verscheidene tumor markers werd door middel van immunohistochemie bepaald.
Histologische gradering was een onafhankelijke prognostische factor voor zowel
totale overleving als metastase vrije overleving. Tumor grootte was een
onafhankelijke prognostische factor voor metastase vrije overleving. Ook in de
subgroep van jonge vrouwen zonder okselklier metastasen bleef histologische
gradering een onafhankelijke prognostische factor wat betreft totale en metastase
vrije overleving.
In Hoofdstuk 9 wordt het effect van adjuvant systemische polychemotherapie
vergeleken bij vrouwen van 40 jaar of jonger ten tijde van de diagnose met
hormoonreceptor-positieve tumoren en hormoonreceptor-negatieve tumoren. De
mediane follow-up bedroeg 7.3 jaar ten tijde van de analyse. In de groep patiënten die
adjuvant systemische chemotherapie kregen was er geen verschil wat betreft
overleving en metastase vrije overleving tussen patiënten met hormoonreceptor-
positieve en hormoonreceptor-negatieve tumoren. In de groep patiënten die geen
chemotherapie ontvingen hadden patiënten met hormoonreceptor-positieve tumoren
een significant betere prognose wat betreft totale overleving en ziektevrije overleving.
Derhalve lijken jonge vrouwen met hormoonreceptor-positieve tumoren minder baat
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te hebben bij chemotherapie dan vrouwen met hormoonreceptor-negatieve tumoren.
In Hoofdstuk 10 worden de resultaten van dit proefschrift geanalyseerd en worden
toekomstperspectieven van klinisch en translationeel onderzoek met betrekking tot
de behandeling van het primair operabel mammacarcinoom besproken.
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